Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

2017

Examining the Regulation of Kv7 K+ Channels in Airway Smooth
Muscle Cells and Their Potential as Novel Therapeutic Targets for
the Treatment of Asthma
Jennifer Haick
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Pharmacology Commons

Recommended Citation
Haick, Jennifer, "Examining the Regulation of Kv7 K+ Channels in Airway Smooth Muscle Cells and Their
Potential as Novel Therapeutic Targets for the Treatment of Asthma" (2017). Dissertations. 2588.
https://ecommons.luc.edu/luc_diss/2588

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2017 Jennifer Haick

LOYOLA UNIVERSITY CHICAGO

EXAMINING THE REGULATION OF Kv7 K+ CHANNELS IN AIRWAY SMOOTH
MUSCLE CELLS AND THEIR POTENTIAL AS NOVEL THERAPEUTIC
TARGETS FOR THE TREATMENT OF ASTHMA

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

PROGRAM IN MOLECULAR PHARMACOLOGY AND THERAPEUTICS

BY
JENNIFER HAICK
CHICAGO, IL
MAY 2017

ACKNOWLEDGEMENTS
I would like to take a moment to thank all of the people who have helped
and supported me these past years while I have been working towards my Ph.D.
First and foremost, I would like to thank Dr. Kenneth Byron for accepting me into
his lab and for his mentorship these past years. The guidance, encouragement,
and open line of communication that was provided throughout my time at Loyola
has been instrumental in shaping me into the scientist that I am today. I will always
be grateful for my training and time spent as a member of the Byron Lab. I would
also like to thank Dr. Lioubov Brueggemann for her patience, her training, and her
friendship. I consider myself extremely lucky to have trained under her and to have
worked alongside her these past years. Outside of training me in the many
techniques essential for the completion of my project, she has also taught me how
to laugh at myself and move past setbacks, because “life is never easy”.
Thank you to my committee members. Dr. Leanne Cribbs, my committee
chair, has been actively involved in my training at Loyola, both the technical skills
that I have learned and the leadership skills that I have developed, and I am
grateful for her mentorship and council. Drs. Tarun Patel and Takeshi Shimamura
have also been instrumental in the development of my project. Their insightful
suggestions and the questions they proposed while discussing my project have
helped me to expand my knowledge and delve deeper into the intricacies of my
project and proposed aims. I am also thankful for the respiratory physiology

iii

expertise provided by Dr. Julian Solway. His knowledge has helped me to examine
the bigger picture surrounding the therapeutic potential of my dissertation work.
I am extremely grateful to Loyola University Chicago and the Department of
Molecular Pharmacology and Therapeutics for the education that I have received
while pursing my degree and for the many opportunities that I have been given to
develop my leadership and communication skills at and away from the bench.
Additionally, I would like to thank the Arthur J. Schmitt Fellowship for providing me
with pre-doctoral funding for the 2015 academic year, as well as for the drive to
become a more active member of my community. Thank you to the Veterans
Affairs for providing the funding for my project, particularly my guinea pig studies,
through Merit Award I01BX007080.
I have been very fortunate to make many friends these past years who have
been there to help troubleshoot experiments, push me to work harder, and provide
the support needed to be successful in my endeavors. In particular, Tom Lynch
and Christina Robakowski have been an invaluable support system both inside
and outside of Loyola. I would also like to thank Maleen Cabe, Brian Lin, Kristin
Hicks, Adam Marek, Harold Bach, Kushal Prajapati, Deep Shah, Anne Roessler,
and Amanda Ward for their friendship and support.
Thank you to my friends outside of Loyola, who have become my second
family, my parents, Craig Haick and Patti Morson, my step-parents, Judi Haick and
Trevor Morson, and my brother, Ryan Haick, for their continuing love and support.
Lastly, my fiancé and best friend, James Groner, for his patience and unconditional
love. He has always believed in me even when I didn’t believe in myself.

iv

For My Parents and My Fiancé

v

TABLE OF CONTENTS
ACKNOWLEDGEMENTS

iii

LIST OF TABLES

ix

LIST OF FIGURES

x

LIST OF ABBREVIATIONS

xii

CHAPTER ONE: INTRODUCTION

1

CHAPTER TWO: LITERATURE REVIEW
Airway Smooth Muscle
Anatomy and physiology of airway smooth muscle
Signal transduction in airway smooth muscle cells
Gq-protein coupled receptor signaling
Gs-protein coupled receptor signaling
Protein kinase C in airway smooth muscle
Regulation of cytosolic Ca2+ in airway smooth muscle
Release of Ca2+ from intracellular stores
Mechanisms of Ca2+ influx
L-type voltage sensitive Ca2+ channels
K+ channels in airway smooth muscle
Asthma
Pathophysiology of asthma
Airway smooth muscle in asthma
Asthma therapy
Airway inflammation
Airway relaxation
Combination therapy
Need for new therapy
Kv7 Potassium Channels
Discovery of Kv7 channels
Structure and composition of functional Kv7 channels
Regulation of Kv7 channels
Transcriptional regulation
Receptor mediated Kv7 current suppression
PIP2 mediated regulation
Ca2+/CaM mediated regulation
Phosphorylation mediated regulation
Pharmacology of Kv7 channels
Expression of Kv7 channels
Kv7 channels in smooth muscle
Kv7 channels in airway smooth muscle
Targeting Kv7 channels in smooth muscle as a therapeutic strategy
vi

3
3
3
3
3
4
5
6
6
7
8
11
12
12
13
14
14
15
16
17
18
19
20
22
22
23
23
24
24
26
28
29
30
31

CHAPTER THREE: HYPOTHESIS AND AIMS

35

CHAPTER FOUR: MATERIALS AND METHODS
Cell Culture
Adenoviral infection
Retroviral infection
Constructs used for infections
Electrophysiology
Immunoprecipitation and Western Blot Analysis
[Ca2+]cyt Measurements with Fura-2
Immunofluorescence
Mass Spectrometry
Enzymatic digestion
High Performance Liquid Chromatography for mass spectrometry
Liquid Chromatography MS/MS analysis
Criteria for protein identification
Post-translation modification site localization
Animal Welfare and Housing
Guinea Pig Sensitization Model
Tissue collection
Precision cut lung slices
Human Precision Cut Lung Slices
Guinea Pig flexiVent Optimization Experiments
Statistics

38
38
39
39
40
40
41
43
44
45
46
47
47
48
49
50
50
51
51
53
54
55

CHAPTER FIVE: RESULTS
56
Cultured HTSMCs Retain SM22α Expression
56
Histamine Increases [Ca2+]cyt in Cultured HTSMCs
56
Activation of PKC Suppresses hKv7.5 Currents in Cultured HTSMCs
58
Activation of PKC Induces Phosphorylation of hKv7.5 Channels in
59
Cultured HTSMCs
PKCα is Necessary for the Regulation of hKv7.5 Currents by Histamine,
62
but not for Channel Phosphorylation
Threonine Residue 505 may not be Necessary for the Regulation of hKv7.5 63
Currents by Histamine
Serine Residue 441 is Necessary for Regulation of hKv7.5 Currents by
66
Histamine, but not for Channel Phosphorylation
Preliminary Mass Spectrometry Results are Inconclusive
67
Retigabine Dose-dependently Relaxes Rat Airways Preconstricted with
70
Methacholine
Formoterol Dose-dependently Relaxes Rat Airways Preconstricted with
74
Methacholine
Retigabine Enhances Formoterol-induced Relaxation of Rat Airways
75
Preconstricted with Methacholine
Retigabine Appears to Enhance Formoterol-induced Relaxation of
76
vii

Human Airways Preconstricted with Histamine
Retigabine Relaxes OVA-sensitized Guinea Pig Airways Preconstricted
with Methacholine
Retigabine Attenuates OVA-induced Allergic Asthma Symptoms in
OVA-sensitized Guinea Pigs
Guinea Pig flexiVent Optimization Experiments and Troubleshooting
CHAPTER SIX: DISCUSSION AND FUTURE DIRECTIONS

78
82
85
90

REFERENCE LIST

108

VITA

127

viii

LIST OF TABLES
Table 1. Preliminary mass spectrometry results

ix

74

LIST OF FIGURES
Figure 1. Schematic of Gq-coupled receptor signaling in ASMCs

9

Figure 2. Cultured HTSMCs express SM22α through passage 8

57

Figure 3. Histamine induces L-type VSCC-dependent increases in [Ca2+]cyt in 58
cultured HTSMCs
Figure 4. Histamine inhibits hKv7.5 currents in cultured HTSMCs

60

Figure 5. Histamine-induced inhibition of hKv7.5 currents in cultured HTSMCs 61
is dependent on PKC
Figure 6. PMA, but not 4α-PMA, inhibits hKv7.5 currents in cultured HTSMCs 63
Figure 7. PKC activation promotes hKv7.5 channel phosphorylation in
HTSMCs

64

Figure 8. Time course of histamine-induced phosphorylation of hKv7.5
channels in cultured HTSMCs

65

Figure 9. PKCα is necessary for histamine-induced inhibition of hKv7.5
67
2+
currents and histamine-induced sustained increases in [Ca ]cyt
in cultured HTSMCs
Figure 10. PKCα is not necessary for histamine-induced increases in
hKv7.5 channel phosphorylation in cultured HTSMCs

69

Figure 11. Threonine 505 may be necessary for histamine-induced inhibition
of hKv7.5 currents in cultured HTSMCs

71

Figure 12. Serine 441 is necessary for histamine- but not PMA-induced
inhibition of hKv7.5 currents in cultured HTSMCs

72

Figure 13. Serine 441 is not necessary for histamine- or PMA- induced
phosphorylation of hKv7.5 channels in cultured HTSMCs

73

Figure 14. Retigabine dose-dependently relaxes rat airways preconstricted
with methacholine

75

Figure 15. Formoterol dose-dependently relaxes rat airways preconstricted
with methacholine

77

x

Figure 16. Retigabine enhances formoterol-induced relaxation of rat airways 79
preconstricted with methacholine
Figure 17. Retigabine attenuates the time-dependent decline in formoterol
induced relaxation of rat airways preconstricted with
methacholine observed upon repetitive administration

80

Figure 18. Retigabine appears to attenuate the time-dependent decline in
formoterol-induced relaxation of human airways preconstricted
with histamine observed upon repetitive administration

81

Figure 19. Retigabine relaxes control guinea pig airways preconstricted with
methacholine

83

Figure 20. Retigabine relaxes OVA-sensitized guinea pig airways
preconstricted with methacholine

84

Figure 21. Repetitive nebulized methacholine dose response with nebulized
retigabine pretreatment

86

Figure 22. Repetitive intravenous histamine with increase concentrations of
nebulized retigabine

88

Figure 23. Nebulized retigabine lowers baseline respiratory resistance

89

Figure 24. Proposed role of Kv7 channels and L-type VSCCs following Gqcoupled receptor signaling in ASMCs

94

xi

LIST OF ABBREVIATIONS
4α-PMA

4α-Phorbol 12-Myristate 13-Acetate

AC

Adenylyl Cyclase

AHR

Airway Hyperresponsiveness

AKAP

A-kinase Anchoring Protein

ASMC

Airway Smooth Muscle Cell

AVP

Arginine8-Vasopressin

BFNC

Benign Familial Neonatal Convulsions

BKCa

Large Conductance Calcium-Activated Potassium Channel

Ca2+

Calcium

[Ca2+]cyt

Cytosolic Calcium Concentration

CaM

Calmodulin

cAMP

Cyclic Adenosine Monophosphate

CCB

Calcium Channel Blocker

CPI-17

PKC-Potentiated Inhibitory Protein for Heterotrimeric MLCP of 17
kDa

DAG

1,2-diacylglycerol

DMEM

Dulbecco's Modified Eagle's Medium

DRG

Dorsal Root Ganglia

EC50

Half-Maximal Effective Concentration

EndoK

Endoproteinase Lys-C

EndoQ

Endoproteinase Glu-C

xii

GFP

Green Fluorescent Protein

hKv7.5

Human Kv7.5 channels

HTSMC

Human Trachealis Smooth Muscle Cell

IgE

Immunoglobulin E

IL-5

Interleukin 5

IL-13

Interleukin 13

IP

Immunoprecipitation

IP3

1,4,5-trisphosphate

IP3R

1,4,5-trisphosphate Receptor

i.v.

Intravenous

I-V

Current-Voltage Relationship

K+

Potassium

KATP

ATP-Sensitive Potassium Channel

KCNQ

Name of Gene Family that Encodes Kv7 Channel Alpha Subunits

Kv

Voltage-Dependent Delayed Rectifier Potassium Channel

Kv7

Family of Voltage Gated Ion Changes Encoded by KCNQ Genes

LABA

Long Acting β2-Agonist

mHBSS

Modified Hank’s Balanced Salt Solution

mKreb’s

Modified Kreb’s Buffer

mRNA

Messenger Ribonucleic Acid

MLC

Myosin Light Chain

MLCK

Myosin Light Chain Kinase

MLCP

Myosin Light Chain Phosphatase

xiii

MOI

Multiplicity of Infection

Na+

Sodium

NCX

Sodium/Calcium Exchanger

NH4HCO3

Ammonium Bicarbonate

PCLS

Precision Cut Lung Slice

PIP2

Phosphatidylinositol 4,5-Bisphosphate

PKA

Protein Kinase A

PKC

Protein Kinase C

PLC

Phospholipase C

PMA

Phorbol 12-Myristate 13-Acetate

PSS

Physiological Saline Solution

REST

Repressor Element 1-Silencing Transcription Factor

ROCC

Receptor Operated Calcium Channel

S385

Serine 385

S441

Serine 441

S441A

Serine 441 Mutated to Alanine

S752

Serine 752

S772

Serine 772

SABA

Short Acting β2-Agonist

SERCA

Sarco/Endoplasmic Reticulum Calcium-ATPase

shControl

Short Hairpin RNA Targeting a Sequence Not Found in the Human
Genome

shPKCα

Short Hairpin RNA Targeting Protein Kinase C Alpha

xiv

shRNA

Short Hairpin Ribonucleic Acid

SOCC

Store Operated Calcium Channel

Sp1

Specialty Factor 1 Transcription Factor

SR

Sarcoplasmic Reticulum

STIM1

Stromal Interaction Molecule 1

T505

Threonine 505

T505A

Threonine 505 Mutated to Alanine

TRP

Transient Receptor Potential

VSCC

Voltage Sensitive Calcium Channel

WHO

World Health Organization

WT

Wild Type

xv

CHAPTER ONE
INTRODUCTION
Asthma is a chronic, heterogeneous disease of the airways in the lung that
affects 235 million people worldwide and is characterized by inflammation of the
airways, airway remodeling, and exaggerated narrowing of the airways, termed
airway

hyperresponsiveness

(AHR)

(WHO

2013,

CDC

2014).

The

hypercontraction of airways occurs in response to a variety of stimuli, or triggers,
such as allergens, cold air, or physical activity. Airway smooth muscle is the
effector behind the hypercontraction, however the specific role that it plays in the
pathophysiology of asthma and AHR remain unclear despite extensive study (An,
Bai et al. 2007). The contractile state of airway smooth muscle is predominantly
determined by Gq-coupled bronchoconstrictor agonist signaling. These agonists
include acetylcholine, histamine, endothelin, and leukotriene D4. Activation of Gqcoupled receptors culminates in an increase in cytosolic calcium [Ca2+]
concentrations ([Ca2+]cyt) that leads to contraction of airway smooth muscle cells
(ASMCs) and airway constriction (Penn 2008). Bronchodilator therapy is one type
of asthma therapy that aims to reverse the airway constriction that results from Gqcoupled receptor signaling, however there are a limited number of therapeutic
targets currently available (Pera and Penn 2016). There is also a large population
of individuals with asthma who have poor control of their disease or develop a
tolerance to currently available treatment options (Peters, Jones et al. 2007,
1
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Chapman, Boulet et al. 2008, Cazzola, Page et al. 2013) indicating the pressing
need to explore new therapeutic targets for bronchodilator therapy and additional
treatment options.
Our lab recently found that Kv7 potassium (K+) channels are expressed in
airway smooth muscle and that Kv7 currents are inhibited upon treatment with Gqcoupled bronchoconstrictor agonists in ASMCs. Blockade of Kv7 channels
resulted in robust constriction of human airways and activation of Kv7 channels
attenuated airway constriction induced by the bronchoconstrictor agonist
histamine (Brueggemann, Kakad et al. 2012). Kv7 channels are well-known
regulators of smooth muscle contractility (Haick and Byron 2016) and are also
recognized as being downstream of Gq-coupled receptor signaling in a variety of
tissues (Marrion 1997, Delmas and Brown 2005, Mackie, Brueggemann et al.
2008). This project aims to elucidate the mechanism of Kv7 K+ channel regulation
by the bronchoconstrictor histamine in airway smooth muscle and to test the
potential of Kv7 channel activators as novel bronchodilatory therapy for the
treatment of asthma.

CHAPTER TWO
LITERATURE REVIEW
Airway Smooth Muscle.
Anatomy and physiology of airway smooth muscle. Airway smooth
muscle is located along the posterior aspect of the trachea and encircles airways
in a helical manner down the bronchial tree. Physiologically, its main purpose is to
establish and regulate airway diameter and therefore the rate of and resistance to
airflow, particularly in disease states. When the cells that compose this layer of
smooth muscle contract, airways constrict, and when the ASMCs relax, airways
also relax. The narrowing and opening of airways are often a result of signal
transduction initiated by mediators released from nearby nerves or cells of the
immune system or epithelium.
Signal transduction in airway smooth muscle cells. Gq-protein
coupled receptor signaling. The contractile state of airway smooth muscle is
largely dictated by the balance of Gs and Gq-coupled receptor signaling, with tone
being established primarily by procontractile Gq-coupled signaling, with minimal
input from prorelaxant Gs-coupled receptor signaling in a non-disease state.
Acetylcholine, a Gq-coupled m3 muscarinic acetylcholine receptor agonist, is
released from nearby parasympathetic nerves and is the principal mediator of
airway smooth muscle tone (Penn 2008). Other Gq-coupled receptor agonists that
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promote contraction of ASMCs include histamine, endothelin, and leukotriene D4
(Penn and Benovic 2008). As depicted in Figure 1, activation of Gq-coupled
receptors results in the activation of phospholipase C (PLC) which in turn cleaves
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3)
and 1,2-diacylglycerol (DAG). DAG activates protein kinase C (PKC), whose
effects will be discussed later in this chapter. IP3 binds to the IP3 receptor (IP3R)
located on the intracellular Ca2+ storage organelle called the sarcoplasmic
reticulum (SR) and induces Ca2+ release into the intracellular space. The newly
released Ca2+ binds to calmodulin, forming Ca2+-calmodulin complexes that
activate myosin light chain (MLC) kinase (MLCK). MLCK phosphorylates MLCs
which promotes the interaction between actin and myosin, called cross-bridge
formation, and the cycling between an interacting and non-interacting state, called
cross-bridge cycling, that causes contraction of the smooth muscle cell (Hall 2000,
Penn 2008, Penn and Benovic 2008).
Gs-protein

coupled

receptor

signaling.

The

counterbalance

to

bronchoconstrictor signaling, and a common target pathway activated by asthma
therapeutics such as β2-adrenergic agonists, is Gs-coupled receptor signaling. The
activation of adenylyl cyclase (AC) following Gs-coupled receptor stimulation
results in the generation of cyclic adenosine monophosphate (cAMP) and the
subsequent activation of protein kinase A (PKA). PKA phosphorylates IP3Rs, Gqcoupled receptors, and MLCK resulting in their inhibition, as well as MLC
phosphatase (MLCP) to promote decreased phosphorylation of MLCs. These
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actions ultimately result in reduced phosphorylation of MLC and therefore reduced
actin and myosin cross-bridge cycling and relaxation of the smooth muscle cell.
Another PKA target is the Ca2+ activated K+ channel, which, when phosphorylated,
has an increased open probability and therefore promotes membrane
hyperpolarization and smooth muscle cell relaxation (Hall 2000, Penn 2008, Penn
and Benovic 2008).
Protein kinase C in airway smooth muscle. The serine and threonine
kinase PKC is widely acknowledged as a mediator of bronchoconstriction. Multiple
isoforms have been observed at the mRNA and protein level in human airway
smooth muscle. Freshly isolated human trachealis and lung tissues express the
Ca2+-dependent conventional isoforms α, β1, and β2, Ca2+-independent novel
isoforms δ, ε, and η, and the atypical isoforms ζ and ι (Webb, Lindsay et al. 1997,
Sakai, Yamamoto et al. 2009). Cultured human airway smooth muscle cells are
reported to express all isoforms except γ, although that particular isoform was not
examined (Carlin, Yang et al. 1999). The PKC isoforms that mediate
bronchoconstriction have not been specified.
As described above, the formation of DAG in ASMCs that follows Gqcoupled receptor activation results in the activation of PKC. PKC acts to
phosphorylate a number of substrates to promote cross-bridge cycling and ASMC
contraction, such as MLCP (Webb, Hirst et al. 2000), calponin (Pohl, Winder et al.
1997), and the PKC-potentiated inhibitory protein for heterotrimeric MLCP of 17
kDa, CPI-17 (Sakai, Chiba et al. 2005). Despite the recognized effects facilitated
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through phosphorylation of ASMC contractile machinery, there are other PKCdependent aspects of ASMC contraction that cannot be explained by these
mechanisms. Some evidence indicates that PKC-mediated contraction of airway
smooth muscle is at least partially dependent on extracellular Ca2+ and L-type
voltage sensitive Ca2+ channel (VSCC) activity (Park and Rasmussen 1985, Knox,
Baldwin et al. 1993, Rossetti, Savineau et al. 1995, Yang and Black 1996,
Mukherjee, Trice et al. 2013), signifying a roll for ionic fluxes from the extracellular
to the intracellular space in airway constriction.
Regulation of cytosolic Ca2+ in airway smooth muscle. The necessity of
Ca2+ for ASMC excitation-contraction coupling has been well established and
multiple participants have been implicated as contributors to the required increase
in cytosolic Ca2+ concentrations ([Ca2+]cyt). Bronchoconstrictor agonist stimulation
of ASMCs results in a biphasic increase in [Ca2+]cyt: an initial, transient phase
mediated primarily by formation of IP3 and release of Ca2+ from intracellular stores
followed by a sustained, plateau phase dependent on the influx of extracellular
Ca2+ (Figure 1).
Release of Ca2+ from intracellular stores in airway smooth muscle
cells. The initial IP3-mediated increase in [Ca2+]cyt happens within seconds (Hall
2000) and stimulates a series of Ca2+ oscillations (Hirota, Helli et al. 2007, Jude,
Wylam et al. 2008) where the newly released Ca2+ activates neighboring IP3Rs
and thus propagates a wave. IP3Rs are inactivated when Ca2+ interacts with a
second inhibitory site or when SR stores are depleted and Ca2+ is removed from
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the intracellular space by sarco/endoplasmic reticulum Ca2+-ATPases (SERCA)
located on the SR membrane or efflux of Ca2+ via sodium (Na+)/Ca2+ exchangers
(NCXs) and plasma membrane Ca2+-ATPases located on the plasma membrane
(Perez-Zoghbi, Karner et al. 2009). Ryanodine receptors have also been
implicated in contributing to Ca2+ release from internal stores and participating in
the Ca2+ oscillations (An, Bai et al. 2007, Hirota, Helli et al. 2007).
Mechanisms of Ca2+ influx in airway smooth muscle cells. An influx of
extracellular Ca2+ is necessary to maintain the increase in [Ca2+]cyt and for
sustained ASMC contraction. Although there is still disagreement as to the
predominant mechanism of this Ca2+ influx, largely due to differences observed
between species or bronchoconstrictor agonists, evidence suggests that there are
voltage-independent and voltage-dependent components. Entry of Ca2+ through
store operated Ca2+ channels (SOCCs), likely involving the Ca2+ store depletion
sensor stromal interaction molecule 1 (STIM1) (Peel, Liu et al. 2006) and the Ca2+
release-activated Ca2+ channel protein Orai 1 (Peel, Liu et al. 2008), is one voltageindependent mechanism that has been implicated in Ca2+ influx in ASMCs.
Receptor operated Ca2+ channels (ROCCs) have also been indicated as a
mechanism of Ca2+ influx. Transient receptor potential (TRP) channels have been
indicated as both SOCCs and ROCCs (Gosling, Poll et al. 2005, Perez-Zoghbi,
Karner et al. 2009, Wang and Zheng 2011). Lastly, the NCX is thought to switch
to reverse mode upon an accumulation of Na+ in the intracellular space and/or a
change in membrane potential in ASMCs to promote Ca2+ influx (Hirota, Pertens
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et al. 2007). The voltage-dependent element of Ca2+ influx is evidenced to occur
through L-type VSCCs.
L-type voltage sensitive Ca2+ channels in airway smooth muscle cells.
L-type VSCC currents have been identified in ASMCs from multiple species
(Hirota, Helli et al. 2007), including human (Marthan, Cecile et al. 1989, Worley
and Kotlikoff 1990). Their role in vascular smooth muscle cell contraction is well
understood, however the debate over their importance in ASMC contraction wages
on. L-type VSCCs are activated by membrane depolarization. More specifically,
the channels activate when membrane voltages reach -45 to -25 millivolts (mV),
are maximally active at 0 to +20 mV, and are blocked by dihydropyridines,
phenylalkylamines,

or

inorganic

cations

(Hirota,

Helli

et

al.

2007).

Bronchoconstrictor agonists induce ASMC membrane depolarization (Janssen
and Killian 2006, Hirota, Helli et al. 2007, Byron, Brueggemann et al. 2014, Haick,
Brueggemann et al. 2017) and in many instances L-type VSCC blockers have
been shown to reverse the effects of bronchoconstrictors, such as Ca2+ influx
(Flores-Soto, Reyes-Garcia et al. 2013) and ASMC contraction (Kamishima,
Nelson et al. 1992, Watts, Cox et al. 1994, Dai, Kuo et al. 2007, Hirota and Janssen
2007). Although there is some evidence of a lesser role for L-type VSCCs in Ca2+
influx in ASMCs (Murray and Kotlikoff 1991, Janssen 2002, Janssen and Killian
2006), there is clinical evidence that offers support for their role in the regulation
of airway diameter.

9

Figure 1. Schematic of Gq-coupled receptor signaling in ASMCs. Activation of
Gq-coupled receptors by bronchoconstrictor agonists (such as histamine,
acetylcholine, endothelin, leukotriene D4) results in the activation of phospholipase
C (PLC), the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol
1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 binds to the IP3
receptor located on the sarcoplasmic reticulum (SR), promoting Ca2+ release into
the intracellular space. This is the initial transient phase of increased cytosolic
Ca2+. Sustained contraction of ASMCs requires an influx of Ca2+ from the
extracellular space. This occurs through receptor operated Ca2+ channels
(ROCCs), store operated Ca2+ channels (SOCCs), L-type voltage sensitive Ca2+
channels (VSCCs) and reversal of the Na+/Ca2+ exchanger. Ca2+ binds to
calmodulin (CaM), forming the Ca2+/CaM complex and activates myosin light chain
kinase (MLCK). MLCK phosphorylates myosin light chains and promotes actin and
myosin cross-bridge formation and ASMC contraction.
In the 1980’s, the calcium channel blockers (CCBs) nifedipine and
verapamil underwent numerous clinical trials for the treatment of asthma with
variable amounts of bronchoprotection observed, from no protection to significant
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protection. Overall, they have been deemed an ineffective treatment despite the
fact that many studies contained at least a subset of asthmatic patients that
benefited from CCB treatment (Fish 1984, Barnes 1985, Fanta 1985, Solway and
Fanta 1985). Although it is important to acknowledge evidence on both sides of
the controversy, there are certain considerations to be made for re-evaluating the
potential of L-type VSCCs as therapeutic targets for asthma. Multiple studies have
indicated that the effectiveness of CCBs appears to be dependent on
bronchoconstrictor agonist concentration or the extent of bronchial provocation. At
low concentrations of the bronchoconstrictor methacholine, rat airway constriction
was reversed upon treatment with the VSCC blocker verapamil, however this was
not the case when airways were exposed to high concentrations of methacholine
(Byron, Brueggemann et al. 2014). A similar bronchoconstrictor concentrationdependence was observed for verapamil-induced relaxation of acetylcholineinduced contraction of canine trachealis; verapamil attenuated agonist-induced
contraction of the smooth muscle, but only at low acetylcholine doses (Farley and
Miles 1978). In human trials, oral nifedipine was only effective at attenuating
isocapnic hyperventilation of cold air at lower and intermediate minute ventilation
rates (Solway and Fanta 1985). These results suggest that there are different
sources of Ca2+, perhaps a voltage-dependent source with submaximal stimulus
versus voltage-independent source with maximum stimulus, for ASMC contraction.
Other considerations include the fact that cardiovascular side-effects have limited
the maximum concentration of CCB that can be used, as has formulation
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development (Fish 1984, Barnes 1985, Solway and Fanta 1985). Despite the fact
that clinical trials using CCBs were largely deemed unsuccessful, targeting
different players in this pathway remains a viable option for the treatment of asthma
and should be explored.
K+ channels in airway smooth muscle. The resting membrane potential
of human ASMCs ranges from -45 to -60 mV and oscillates in slow waves, however
the oscillations rarely result in the generation of spontaneous action potentials due
to the strong outward rectification of K+ through K+ channels that promotes
membrane hyperpolarization (Thirstrup 2000). Inhibition of the outward K+ currents
results in the induction of action potentials (Marthan, Cecile et al. 1989). One family
of K+ efflux mediators found in ASMCs, and the most important in terms of
membrane potential regulation, are voltage-dependent delayed rectifier K+ (Kv)
channels (Kotlikoff 1990, Boyle, Tomasic et al. 1992, Fleischmann, Washabau et
al. 1993, Hall 2000, An, Bai et al. 2007, Hirota, Helli et al. 2007). Large
conductance Ca2+-activated K+ (BKCa) channels, whose hyperpolarizing currents
are involved in β2-agonist mediated airway relaxation (Kume, Hall et al. 1994), and
ATP-sensitive K+ (KATP) channels, believed to have little, if any, impact on ASMC
contraction or relaxation, are also expressed in ASMCs (Hall 2000, Liu and Xu
2005, Hirota, Helli et al. 2007).
Different subtypes of Kv channels have been found to be expressed in
ASMCs. Kv1.2, Kv1.5, and Kv1.1 channels have been detected at the mRNA level
in subcultured human trachealis and bronchial myocytes (Adda, Fleischmann et
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al. 1996) while Kv7.1, Kv7.4, and Kv7.5 channels have been detected at the mRNA
level in freshly isolated human trachealis smooth muscle (Brueggemann, Kakad et
al. 2012). Some evidence exists that Kv currents in rat and human ASMCs are
inhibited upon activation of PKC (Liu, Xu et al. 2003, Cheng, Xu et al. 2007), and
Kv7 currents in freshly isolated guinea pig ASMCs are inhibited following treatment
with bronchoconstrictor agonists (Brueggemann, Kakad et al. 2012). However, the
specific mechanism(s) behind this current inhibition or how to exploit this
knowledge for a therapeutic benefit have yet to be explored.

Asthma.
Pathophysiology of asthma. Asthma is a chronic disease of the airways
that affects an estimated 235 million people worldwide (WHO 2013). In the United
States specifically, more than 25 million people have asthma, with 7 million of
those cases affecting children (CDC 2014). Asthma is characterized by reversible,
exaggerated obstruction to airflow that results from a combination of AHR, chronic
airway inflammation, increased mucus production, and airway remodeling that
ultimately results in the thickening of airway walls (Fanta 2009, Kudo, Ishigatsubo
et al. 2013, Olin and Wechsler 2014). To briefly summarize an extensive and
complicated aspect of the disease, the chronic airway inflammation results from
an increased infiltration of immune cells, such as mast cells, eosinophils, and T
cells. These immune cells release mediators, such as cytokines and
bronchoconstrictors, that can trigger bronchoconstriction or promote airway

13
remodeling (Hamid and Tulic 2009). The remodeling is principally an expansion of
non-smooth muscle connective tissue and smooth muscle, as well as an increase
in the number of mucus glands. The structural changes, such as increased airway
smooth muscle mass and fibrosis below the epithelium, associated with airway
remodeling are often a consequence of the tissue damage that results from chronic
inflammation and inflammatory mediator release (Homer and Elias 2005).
Airway smooth muscle in asthma. Airway smooth muscle is known to
have multiple roles in the asthmatic disease state. Hyperplasia and hypertrophy of
ASMCs are linked to the increased airway smooth muscle mass associated with
airway remodeling (Homer and Elias 2005, Prakash 2013). ASMCs also secrete a
variety of factors, including cytokines that affect the inflammatory state of
surrounding tissue and molecules that participate in growth and remodeling (Xia,
Redhu et al. 2013). Airway smooth muscle is most well known as the contractile
effector of the hyperresponsiveness associated with asthma. A hallmark of
asthma, AHR is the nonspecific, exaggerated constriction of airway smooth muscle
in response to stimuli such as bronchoconstrictor agonists, cold air, or exercise.
AHR is attributed to an increase in sensitivity of asthmatic airways, however the
extent to which functional, structural, or molecular properties of airway smooth
muscle contributes to the increased sensitivity remains unclear (An, Bai et al. 2007,
Pascoe, Wang et al. 2012, Lauzon and Martin 2016).
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Asthma therapy. Airway inflammation. One important goal of asthma
therapy is to reduce and prevent, or even eliminate, the inflammation associated
with the disease. Corticosteroids are the most frequently used therapeutic option
to manage airway inflammation. Briefly, the glucocorticoid binds to its receptor in
the cytosol and the newly formed complex translocates to the nucleus where it
dimerizes with another glucocorticoid-receptor complex, binds to the glucocorticoid
response element on the promoter region of specific DNA sequences, and exerts
its effects through regulation of gene transcription. Examples of these inflammatory
suppressive effects include decreased cytokine and inflammatory mediator
production and increased anti-inflammatory mediator production (Umland,
Schleimer et al. 2002).
Although corticosteroids are considered to be the most efficacious form of
anti-inflammatory therapy for asthma, they do not suppress all inflammatory
responses – including leukotriene production. Leukotrienes are inflammatory
mediators that participate in the pathogenesis of asthma by acting as
chemoattractants, promoting mucus secretion, and inducing airway smooth
muscle proliferation. Cysteinyl conjugate leukotrienes also act as potent
bronchoconstrictors. Leukotriene modifiers are another class of anti-inflammatory
asthma therapeutics that act to either inhibit the synthesis of leukotrienes or
antagonize their actions at leukotriene receptors (Salvi, Krishna et al. 2001).
In cases of severe allergic asthma or corticosteroid-resistant asthma, antiIgE therapy is one of the newer anti-inflammatory approaches to treatment. The
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anti-IgE antibodies bind to serum IgE and prevent IgE from binding to its receptor
located on effector cells, such as mast cells and basophils, thus averting the
cellular response to allergens that manifests in asthmatic symptoms, such as
inflammation and allergen-induced bronchoconstriction (D'Amato, Stanziola et al.
2014). Targeting specific inflammatory agents to modify the immunologic
responses associated with cytokine cell signaling is one of the new approaches
being undertaken to better control asthmatic symptoms. Antibodies against IL-5
and IL-13 are two examples of potential treatment options that have undergone
clinical trials with promising results (Olin and Wechsler 2014, Pera and Penn
2016).
Airway relaxation. Another essential goal of asthma therapy is to prevent
or attenuate the exaggerated airway constriction associated with the disease. The
most common targets for bronchodilator therapy are the G-protein coupled
receptors located on airway smooth muscle that are involved in the regulation of
its contractile state. Opposing the downstream effects of Gq-coupled agonists by
activating the Gs-coupled receptor pathway is one method to promote airway
relaxation (Pera and Penn 2016). The β2-adrenergic receptor has been the primary
target of bronchodilator therapy for decades. The initial β2-agonists exhibited a
short duration of action, now referred to as short acting β2-agonists (SABAs), and
are currently used as “rescue” medications for acute asthma attacks. Long acting
β2-agonists (LABAs) were developed with the purpose of extending the duration of
action of β2-agonist therapy and are currently used as “maintenance” therapy
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(Cazzola, Page et al. 2013). Other Gs-coupled receptors that relax airway smooth
muscle when activated include bitter taste receptors, which promote ASMC
relaxation via activation of BKCa channels, and prostaglandin E2 receptors, which
exert their actions via traditional Gs-protein coupled receptor signaling. The
development of therapeutic agonists for these receptors, however, has yet to be
completed (Dowell, Lavoie et al. 2014).
Antagonizing Gq-coupled muscarinic receptors is another therapeutic
approach currently utilized to relax airways, particularly when corticosteroid and
LABA therapy is insufficient for symptom management. By competing with
acetylcholine for the muscarinic receptors, muscarinic antagonists promote
bronchodilation and also have the potential to attenuate acetylcholine-induced
inflammation and mucus secretion that contribute to the pathophysiology of
asthma (Busse, Dahl et al. 2016, D'Amato, Vitale et al. 2017).
Combination therapy. Seeing as there are multiple components that
contribute to the pathology of asthma, such as inflammation and excessive
bronchoconstriction, a combination of therapeutic approaches is necessary to
manage the disease symptoms. The most commonly prescribed therapy is the
combination of a LABA and an inhaled corticosteroid (Cazzola, Page et al. 2013,
Ricciardolo, Blasi et al. 2015). There are also new studies that indicate the
beneficial effects of combining a LABA with a long-acting muscarinic receptor
antagonist (Ricciardolo, Blasi et al. 2015), introducing the possibility of a more
advanced combination therapy that may become available in the future.
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Need for new therapy. Mainstream asthma therapy has remained
relatively constant over the past few decades. Some enhancements have been
made to improve the duration or specificity of current treatment options, however
the most common courses of action have not changed. Despite the improvements
made and the continued research into new asthma therapeutics, it has been
reported in some studies that greater than 50% of the asthmatic population have
poor control over their symptoms (Peters, Jones et al. 2007, Chapman, Boulet et
al. 2008). Inadequately controlled asthma leads to not only a poorer quality of life
for the patient but also an increased financial burden on the patient and healthcare
system (Busse, Dahl et al. 2016). One cause of the poor symptom management is
the tolerance, or tachyphylaxis, that develops upon extended used of β2-agonists.
This manifests as decreased sensitivity to bronchodilator therapy that is believed
to occur as a result of desensitization of the β2-receptor (Cazzola, Page et al. 2013,
Pera and Penn 2016). There is also a portion of the asthmatic population that does
not benefit from the standard inhaled corticosteroid therapy. Many of these patients
attempt to control their asthma with high doses of oral corticosteroid therapy,
however the high dose and delivery method make the patients more prone to the
negative side effects of treatment (Ricciardolo, Blasi et al. 2015, Pera and Penn
2016).
It is clear that new therapeutic options must be explored to meet the
pressing need for additional asthma treatment options. The prevalence of asthma
is expected to continue to rise, leading to potentially even more individuals with
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poorly managed disease symptoms. The research presented in this dissertation
suggests that targeting Kv7 K+ channels with channel activators may be a novel
and efficacious approach to asthma therapy, potentially meeting the currently
unmet need.

Kv7 Potassium Channels.
Kv7 K+ channels were named by the International Union of Pharmacology
based on the phylogenetic relationships established for Kv1-Kv9 channels. There
are five subtypes, Kv7.1-Kv7.5, whose five gene names, KCNQ1-KCNQ5, were
established by the Human Genome Organization Nomenclature Committee
(Gutman, Chandy et al. 2005). The Kv7 and KCNQ nomenclature are used
interchangeably when discussing the channel protein.
The outwardly rectifying K+ currents conducted by Kv7 channels have three
distinct biophysical properties (Marrion 1997). (1) The threshold of activation of
Kv7 current is approximately -60 mV, which is similar to the resting membrane
potential of excitable cells such as neurons, (2) the current produced following
membrane depolarization is enhanced in a slow and voltage-dependent manner,
and (3) the current does not inactivate. These properties make Kv7 channels
uniquely qualified to set and maintain the resting membrane potential of neurons
and other excitable cells. Additional channel activation that occurs as a result of
membrane depolarization opposes additional depolarization while promoting
repolarization, therefore opposing prolonged firing of action potentials. Conversely,
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if these channels are no longer able to function, either due to mutation or inhibition,
the membrane potential would be expected to trend more positive, leading to
increased firing of action potentials.
Discovery of Kv7 channels. The Kv7.1 subtype, the first of the Kv7
channel family to be identified, was initially discovered in the heart (Sanguinetti,
Curran et al. 1996). Kv7.1 α-subunits form a homotetramer that, with the aid of two
auxiliary subunits (see structure and composition of functional channels section
below), mediate the slow delayed rectifier current IKS, which contributes to the
repolarization of the cardiac action potential (Barhanin, Lesage et al. 1996,
Sanguinetti, Curran et al. 1996).
“M-currents” were first isolated in frog sympathetic neurons nearly four
decades ago (Brown and Adams 1980). This outwardly rectifying K+ current,
named after their suppression following the activation of muscarinic receptors
(Kobayashi and Libet 1968, Weight and Votava 1970, Krnjevic, Pumain et al.
1971), is slow to activate, does so in a voltage-sensitive manner, and exhibits little,
if any, inactivation during sustained membrane depolarizations. Due to the
negative threshold of activation, approximately -60 mV, these currents promote the
stabilization of the negative membrane voltage in neurons and act to suppress
neuronal excitability (Brown and Adams 1980). It wasn’t until the late 1990’s that
the gene products responsible for producing the M-current were identified. When
messenger RNAs encoding human KCNQ2 (Kv7.2) and rat KCNQ3 (Kv7.3) were
co-injected into Xenopus oocytes, the resulting current resembled that of the M-
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current observed in neurons. Similar to endogenous M-currents in sympathetic
neurons, these exogenous currents were sensitive to the Kv7 channel blockers
linopirdine and XE991, providing additional evidence for the identification of the K+
channel family behind the M-current (Wang, Pan et al. 1998).
Structure and composition of functional Kv7 channels. Functional Kv7
channels are formed homo- or heterotetramers of α-subunits. Each α-subunit has
six transmembrane domains (S1-S6) that contain a voltage sensor domain (S4)
and a single pore loop between the S5-S6 domains that acts as a selectivity filter
when the four subunits are assembled (Jentsch 2000). Both the amino and carboxy
termini of each Kv7 subunit are intracellular. The amino terminus is evidenced to
be involved in the localization of Kv7.1 channels to the membrane and it is believed
to play a role in the open probability of Kv7.2/Kv7.3 channels (Choveau and
Shapiro 2012). More comprehensive studies have taken place examining the
different aspects of the long carboxy termini of Kv7 channels, which are comprised
of four helical regions, A-D. Helices A and B are primarily recognized for their
critical interaction with calmodulin (CaM) (Yus-Najera, Santana-Castro et al. 2002,
Haitin and Attali 2008), while the coiled-coil domains, helices C and D, are believed
to be responsible for determining the subunit specificity of channel assembly
(Schwake, Jentsch et al. 2003, Schwake, Athanasiadu et al. 2006, Haitin and Attali
2008). There are also regions of the C-terminus that are critical for channel
trafficking, assembly, cell surface expression, and gating (Haitin and Attali 2008)
as well as interactions with scaffolding proteins, such as A-kinase anchoring
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proteins (AKAPs) (Hoshi, Zhang et al. 2003, Haitin and Attali 2008). The Cterminus also contains amino acid residues that are phosphorylated by a variety
of kinases, such as PKC (Hoshi, Zhang et al. 2003) and Src tyrosine kinase
(Gamper, Stockand et al. 2003), that have the potential to modify channel function.
All five Kv7 subtypes are able to form homotetramers, however
heteromization is limited to specific combinations. Kv7.1 does not co-assemble
with any other channel subtype. Co-expression studies have revealed that Kv7.3
and Kv7.2 can form functional heteromers (Wang, Pan et al. 1998), Kv7.4
heteromizes with Kv7.3 (Kubisch, Schroeder et al. 1999), and Kv7.5 can coassemble with Kv7.3 (Schroeder, Hechenberger et al. 2000) and Kv7.4 (Bal,
Zhang et al. 2008, Brueggemann, Mackie et al. 2014, Chadha, Jepps et al. 2014).
Auxiliary β-subunits are often important determinants of the expression and
function of Kv channels (Brueggemann, Gentile et al. 2013). With regard to Kv7
channels, there is considerable evidence that KCNE1 (also called minK) and
KCNE2-5 (or minK-related peptides), can associate with and regulate channel
expression and function. KCNE1 is the best studied due to its partnership with
Kv7.1 to mediate IKS in cardiac myocytes. Two KCNE1 subunits are thought to
associate with a homotetramer of Kv7.1 α-subunits to form functional channels that
give rise to the slowly activating IKs current (Morin and Kobertz 2008). The
presence of KCNE1 is responsible for the slow channel activation (Sanguinetti,
Curran et al. 1996) and it also increases channel conductance (Pusch 1998).
There is limited information on the roles of natively expressed KCNE subunits in
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modulating Kv7 channel expression and function in tissues other than the heart,
but KCNE subtypes have been found to modulate the function of Kv7 channel
subtypes in expression systems. For example, KCNE2 decreases Kv7.1 current
density (Tinel, Diochot et al. 2000) and KCNE3 greatly enhances Kv7.1 current
density (Bendahhou, Marionneau et al. 2005), while KCNE4 and 5 both suppress
Kv7.1 currents (Angelo, Jespersen et al. 2002, Grunnet, Jespersen et al. 2002,
Grunnet, Olesen et al. 2005). KCNE1 enhances Kv7.5 currents while slowing their
activation (Roura-Ferrer, Etxebarria et al. 2009), KCNE2 accelerates the activation
and deactivation kinetics of Kv7.2/3 currents (Tinel, Diochot et al. 2000), KCNE3
suppresses Kv7.4 (Schroeder, Hechenberger et al. 2000) and Kv7.5 (RouraFerrer, Etxebarria et al. 2009) currents, whereas KCNE4 increases Kv7.4 current
amplitude (Strutz-Seebohm, Seebohm et al. 2006, Jepps, Carr et al. 2015).
Regulation of Kv7 channels. Transcriptional regulation. Although the
functional importance of Kv7 channels in a variety of tissues is acknowledged and
continues to be an area of intense study, little is known about the mechanisms
governing transcriptional regulation of the channels. Expression of KCNQ2 and
KCNQ3 genes is activated by the specialty factor 1 (sp1) in dorsal root ganglia
(DRG) neurons (Mucha, Ooi et al. 2010), however little else is known in regards to
transcriptional activation of KCNQ genes. A slightly more widespread research
effort has been put into examining repression of KCNQ gene expression by
repressor element 1-silencing transcription factor (REST), a transcriptional
repressor whose levels are increased in response to inflammation. Functional

23
binding sites for REST are present in KCNQ2, KCNQ3, KCNQ5 (Mucha, Ooi et al.
2010), and KCNQ4 (Iannotti, Barrese et al. 2013) genes. Treatment of DRG
neurons with inflammatory mediators (Mucha, Ooi et al. 2010) and a neuropathic
injury rat model (Rose, Ooi et al. 2011) demonstrated an increase in REST
expression that correlated with a decrease in Kv7.2 expression. These
observations have led to the hypothesis that REST-induced Kv7.2 downregulation
may be a mechanism that contributes to neuronal over-excitability associated with
neuropathic pain.
Receptor mediated Kv7 current suppression. The suppression of Kv7
currents following activation of a variety of Gq-coupled receptors has been widely
studied ever since the first instance of M-current inhibition was observed in 1980
(Brown and Adams 1980). Stimulation of Gq-coupled receptors found in neurons
(Marrion 1997, Delmas and Brown 2005), vascular smooth muscle cells (Mackie,
Brueggemann et al. 2008, Mani, O'Dowd et al. 2013), and ASMCs (Brueggemann,
Kakad et al. 2012, Evseev, Semenov et al. 2013, Brueggemann, Haick et al. 2014)
results in Kv7 current inhibition.
PIP2 mediated regulation. One consequence of Gq-coupled receptor
activation is the activation of PLC and subsequent hydrolysis of PIP2 to IP3 and
DAG. Once it was established that PIP2 depletion was the mechanism for Mcurrent inhibition following muscarinic receptor activation (Suh and Hille 2002),
numerous studies have examined the necessity of PIP2 for Kv7 channels to remain
open (Zhang, Craciun et al. 2003, Delmas and Brown 2005, Suh and Hille 2008),
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including investigations of the correlation between a channel’s affinity for PIP2
being related to its open probability (Li, Gamper et al. 2005).
Ca2+/CaM mediated regulation. Receptor-mediated inhibition of Kv7
currents can also be mediated by Ca2+/CaM, as is the case for M-current
suppression by the hormone bradykinin. The mechanism of M-current inhibition by
bradykinin differs from that of muscarinic receptor-mediated M-current inhibition in
that it is dependent on IP3-mediated Ca2+ release from intracellular stores
(Cruzblanca, Koh et al. 1998). Ca2+ was found to inhibit M-currents with an IC50 of
approximately 100 nM (Selyanko and Brown 1996), a sensitivity that is dependent
on the presence of CaM acting as a Ca2+ sensor (Gamper and Shapiro 2003).
Phosphorylation mediated regulation. Another consequence of Gqcoupled receptor activation is the activation of the serine/threonine kinase PKC.
Past experiments investigating the inhibition of M-currents by phorbol esters, which
directly activate PKC, and PKC inhibitors have yielded variable results (Marrion
1997). The study completed by Hoshi et al. (2003) was pivotal in terms of beginning
to clarify the role of PKC in Kv7 current regulation. AKAP interacts with PKC and
Kv7 channels, among other proteins, to form a signalosome and facilitate signal
transduction. PKC-induced phosphorylation of Kv7.2 channels was attenuated
upon expression of a mutated AKAP that was unable to bind PKC (Hoshi, Zhang
et al. 2003). Since then, AKAP has been deemed necessary for M-current
inhibition following muscarinic receptor stimulation in mice (Tunquist, Hoshi et al.
2008) and has been shown to co-localize with Kv7.2/Kv7.3 heteromers, as well as
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all Kv7 subtypes save for Kv7.1. The interaction between AKAP and Kv7 channels
acts to “sensitize” the channels to muscarinic inhibition (Bal, Zhang et al. 2010).
The role of PKC in Kv7 current regulation is also evident in vascular smooth
muscle. The suppression of native Kv7 currents following treatment with the Gqcoupled receptor agonist arginine8-vasopressin (AVP) was found to be dependent
on the activation of PKC in cultured A7r5 rat aortic smooth muscle cells, that
express Kv7.5 homomeric channels, and freshly isolated rat mesenteric artery
smooth

muscle

cells,

that

express

Kv7.4/Kv7.5

heteromeric

channels

(Brueggemann, Moran et al. 2007, Mackie, Brueggemann et al. 2008,
Brueggemann, Mackie et al. 2014). Treatment of A7r5 cells with AVP resulted in a
PKC-dependent increase in channel phosphorylation of overexpressed Kv7.5, but
not Kv7.4, channels (Brueggemann, Mackie et al. 2014).
Members of the Src family of non-receptor tyrosine kinases are known to
phosphorylate

Kv7

channels,

resulting

in

Kv7

current

inhibition.

Src

phosphorylates Kv7.3, Kv7.4, and Kv7.5 homomeric channels, but not Kv7.1 or
Kv7.2 homomers. This phosphorylation correlates with subunit-specific current
inhibition and slowing of channel activation kinetics (Gamper, Stockand et al.
2003). Native M-currents, produced by Kv7.2/Kv7.3 heterotetramers, were also
suppressed by Src overexpression in rat sympathetic neurons (Gamper, Stockand
et al. 2003), implying the functional importance of Kv7.3 phosphorylation by Src.
Tyrosine residues 67 and 349, located on the amino and carboxy termini of Kv7.3,
respectively, were later found to be necessary for M-current modulation by Src (Li,
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Langlais et al. 2004). The physiological relevance of this channel regulation by Src
remains to be determined.
PKA is yet another kinase that has been implicated in the regulation of Kv7
currents. Activation of the β-adrenergic receptor/cAMP/PKA pathway increased
Kv7.1 current amplitude in cardiomyocytes (Chen and Kass 2011). Kv7.2/Kv7.3
heteromeric currents were enhanced by PKA and Kv7.2 serine 52 was
phosphorylated in a PKA dependent manner in overexpression systems,
(Schroeder, Kubisch et al. 1998) however no association to endogenous M-current
regulation has been established. Application of the PKA catalytic subunit enhanced
Kv7.4 currents, (Chambard and Ashmore 2005) although a link between the PKAdependent regulation of Kv7.4 channels and signaling events that occur in
cochlear outer hair cells have yet to be established. The Gs-coupled receptor
agonist isoproterenol enhanced Kv7.5 homomeric currents, both endogenous and
exogenous, in a PKA-dependent manner in A7r5 rat aortic smooth muscle cells.
Isoproterenol enhanced exogenous Kv7.4/Kv7.5 heteromeric currents to a lesser
extent and had no effect on exogenous Kv7.4 homomeric currents (Mani,
Robakowski et al. 2016). Additional research examining the physiological
relevance of PKA-induced enhancement of Kv7 currents is necessary when
considering the possibility of exploiting this mechanism for therapeutic benefit in a
variety of tissues.
Pharmacology of Kv7 channels. The presence and function of Kv7
channels in various cell and tissue types has been elucidated primarily through the
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development of pharmacological agents that selectively block or activate these
channels. Linopirdine (1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol2-one) was initially observed to be an enhancer of depolarization-induced
neurotransmitter release and ultimately found to do so via its inhibitory actions on
M-currents (Aiken, Lampe et al. 1995). Both linopirdine, and it’s more potent
analog XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone), are the most
widely used experimental Kv7 channel blockers, effectively block all five Kv7
subtypes, and are largely specific for Kv7 channels at concentrations up to 10 µM
(Schnee and Brown 1998, Wang, Pan et al. 1998, Wang, Brown et al. 2000,
Wladyka and Kunze 2006). Chromanol 293B
(trans-N-[6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-Nmethyl-ethanesulfonamide) (Busch, Suessbrich et al. 1996, Bleich, Briel et al.
1997)

and

HMR-1556

(N-[3-Hydroxy-2,2-dimethyl-6-(4,4,4-trifluoro-butoxy)-

chroman-4-yl]-N-methyl-methanesulfonamide) (Thomas, Gerlach et al. 2003) are
reported to be specific blockers of the Kv7.1 channel subtype.
The Kv7 channel pharmacological toolbox also contains a variety of channel
activators.

Flupirtine

pyridinyl]carbamic

acid

([2-Amino-6-[[(4-fluorophenyl)methyl]amino]-3ethyl

ester)

and

retigabine

(N-(2-Amino-4-(4-

fluorobenzylamino)phenyl)carbamic acid ethyl ester) are the most frequently used
Kv7 channel activators. These drugs activate only Kv7.2-Kv7.5 channels; the
Kv7.1 subtype lacks a critical tryptophan residue required for activation by either
compound (Tatulian, Delmas et al. 2001, Schenzer, Friedrich et al. 2005). L-
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364373 (also known as R-L3; 5-(2-Fluorophenyl)-1,3-dihydro-3-(1H-indol-3ylmethyl)-1-methyl-2H-1,4-benzodiazepin-2-one) is reported to activate only Kv7.1
channels (Salata, Jurkiewicz et al. 1998, Seebohm, Pusch et al. 2003). Other Kv7
activators include ICA-27243 (N-(6-chloropyridin-3-yl)-3,4-difluorobenzamide), a
more effective activator of Kv7.2/Kv7.3 heterotetramers compared to Kv7.1, Kv7.3
or Kv7.4 homotetramers and Kv7.3/Kv7.5 heterotetramers (Wickenden, Krajewski
et al. 2008, Padilla, Wickenden et al. 2009), and its analog, ICA-069673 (N-(2Chloro-5-pyrimidinyl)-3,4-difluorobenzamide), an activator that enhanced Kv7.4
homotetramer currents to a greater extent than Kv7.5 homotetramer currents
(Brueggemann,

Haick

et

al.

2014).

Diclofenac

(2-[2-(2,6-

dichloroanilino)phenyl]acetic acid) is unique in that it was found to enhance
currents from Kv7.4 homotetramers but block currents from Kv7.5 homotetramers,
with

only

moderate

inhibition

of

currents

Kv7.4/Kv7.5

heterotetramers

(Brueggemann, Mackie et al. 2011).
Expression

of

Kv7

channels.

Cardiomyocytes

express

Kv7.1

homotetramers that, with the help of KCNE1 β-subunits, mediate IKS (Barhanin,
Lesage et al. 1996, Sanguinetti, Curran et al. 1996). Mutations in Kv7.1 often result
in a cardiac condition called long QT syndrome where delayed repolarization of
the cardiac action potential can cause potentially fatal cardiac arrhythmias (Chiang
and Roden 2000). In neurons, Kv7.2 and Kv7.3 are the predominant Kv7 subtypes
expressed and they form heterotetramers responsible for the M-current, although
expression of Kv7.5 has also been confirmed (Jentsch 2000). Mutations in Kv7.2
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and Kv7.3 channels cause a reduction of M-current and result in a neonatal form
of epilepsy called benign familial neonatal convulsions (BFNC) (Biervert,
Schroeder et al. 1998, Singh, Charlier et al. 1998, Jentsch 2000). Kv7.4 channels
mediate IKN, a Kv current that opposes the excitability of the specialized sensory
neurons in the sensory outer hair cells of the cochlea. Mutations in Kv7.4 result in
an autosomal dominant progressive deafness that results from eventual
degradation of the sensory hair cells (Kubisch, Schroeder et al. 1999, Kharkovets,
Hardelin et al. 2000). Multiple Kv7 subtypes are expressed in skeletal muscle cells
(Iannotti, Panza et al. 2010) and Kv7.5 in particular has been implicated in the
regulation of the proliferation and differentiation of myoblasts (Roura-Ferrer, Sole
et al. 2008). Functional Kv7 channels have also been discovered in a wide variety
of smooth muscle tissues (see Kv7 channels in smooth muscle and Kv7 channels
in airway smooth muscle sections below).
Kv7 channels in smooth muscle. Kv7 channels are expressed in a variety
of different types of smooth muscle (Greenwood and Ohya 2009, Jepps, Olesen
et al. 2013, Stott, Jepps et al. 2014, Haick and Byron 2016). Smooth muscle
located in the gastrointestinal tract (Ohya, Asakura et al. 2002, Jepps, Greenwood
et al. 2009, Ipavec, Martire et al. 2011, Adduci, Martire et al. 2013), bladder (Rode,
Svalo et al. 2010, Svalo, Hansen et al. 2012, Afeli, Malysz et al. 2013, Anderson,
Carson et al. 2013, Svalo, Bille et al. 2013, Provence, Hristov et al. 2015, Svalo,
Sheykhzade et al. 2015), and myometrium (Aaronson, Sarwar et al. 2006,
McCallum, Greenwood et al. 2009, McCallum, Pierce et al. 2011) of multiple
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species express Kv7 channels that regulate the contractile state of the smooth
muscle they are located in; treatment of tissue preparations with Kv7 channel
inhibitors induces contraction of visceral smooth muscle while treatment with Kv7
channel activators relaxes visceral smooth muscle.
The expression of Kv7 channels has also been observed in a variety of
vascular smooth muscle beds in mice (Ohya, Asakura et al. 2002, Ohya, Sergeant
et al. 2003, Yeung, Pucovsky et al. 2007, Yeung, Schwake et al. 2008, Lee, Yang
et al. 2015), rats (Mackie, Brueggemann et al. 2008, Joshi, Sedivy et al. 2009,
Zhong, Harhun et al. 2010, Mani, Brueggemann et al. 2011, Chadha, Zunke et al.
2012, Khanamiri, Soltysinska et al. 2013, Zavaritskaya, Zhuravleva et al. 2013,
Jepps, Carr et al. 2015, Morales-Cano, Moreno et al. 2015), pigs (Hedegaard,
Nielsen et al. 2014), and humans (Ng, Davis et al. 2011), with many accompanying
functional studies that emphasize the importance of Kv7 channels in the regulation
vascular tone in these different vessels. Studies cited above emphasize that the
regulation of vascular tone occurs due to the role of Kv7 channels in regulating the
membrane potential of vascular smooth muscle cells; inhibition of Kv7 channels
depolarizes vascular smooth muscle cell membranes and initiates contraction of
vascular smooth muscle (Mackie, Brueggemann et al. 2008).
Kv7 channels in airway smooth muscle. Kv7 channels were recently
found to be expressed in airway smooth muscle. Guinea pig ASMCs express
primarily Kv7.2, Kv7.4 and Kv7.5, (Brueggemann, Kakad et al. 2012), whereas
human, mouse and rat airways express Kv7.1, Kv7.4 and Kv7.5, with little to no
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expression of Kv7.2 and Kv7.3 (Brueggemann, Kakad et al. 2012, Evseev,
Semenov et al. 2013, Brueggemann, Haick et al. 2014). The importance of Kv7
channels as determinants of airway smooth muscle excitability has been
emphasized by the electrophysiological and functional studies that have been
completed in these tissues. Carbachol, methacholine, and histamine, Gq-coupled
receptor agonists, inhibited Kv7 currents in freshly isolated airway myocytes from
mouse, rat and guinea pig, respectively (Brueggemann, Kakad et al. 2012, Evseev,
Semenov et al. 2013, Brueggemann, Haick et al. 2014). Activation of Kv7 channels
was found to reverse airway constriction in rat (Brueggemann, Haick et al. 2014)
and human precision cut lung slices (Brueggemann, Kakad et al. 2012), as well as
contraction of mouse and rat tracheal rings (Evseev, Semenov et al. 2013).
Evidence also suggests that nebulized retigabine may act as a bronchodilator in
vivo. Evseev and colleagues found that retigabine attenuated the methacholineinduced increase in enhanced pause (an indirect measurement of airway
resistance (Lomask 2006, Frazer, Reynolds et al. 2011)), in mice (Evseev,
Semenov et al. 2013).
Targeting Kv7 channels in smooth muscle as a therapeutic strategy.
The effects of modulating Kv7 channel activity in the smooth muscle beds listed
above suggest that Kv7 channels may be novel therapeutic targets for a variety of
conditions. Fortunately there are some Kv7 channel activators that are currently in
clinical use for other applications. Flupirtine, while only clinically available as an
analgesic in Europe, has been granted permission to be used in clinical trials in
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the United States for the treatment of fibromyalgia. Retigabine has been clinically
available in the United States as an adjuvant treatment for epilepsy in adults since
mid-2011 (Harris and Murphy 2011) and although celecoxib’s current clinical use
is limited to anti-inflammatory pain relief (McCormack 2011), it has been shown to
enhance Kv7 currents in vascular and airway smooth muscle cells (Brueggemann,
Mackie et al. 2009, Mani, Brueggemann et al. 2011, Brueggemann, Kakad et al.
2012). Repurposing these drugs for the treatment of smooth muscle disorders is
an attractive prospect and may be applicable for a number of diseases.
Targeting Kv7 channels in the gastrointestinal tract may be a novel
approach to treat functional dyspepsia or irritable bowel syndrome, both conditions
associated with gastrointestinal mobility (Leake 2013, Soares 2014). Relaxing the
smooth muscle found in the bladder with Kv7 channel activators may help to
relieve symptoms associated with overactive bladder. Interestingly, and in support
of this theory, urinary retention is one side effect associated with taking retigabine
for the treatment of epilepsy (Brickel, Gandhi et al. 2012). Lastly, suppressing
myometrial contraction is one therapeutic approach currently used to delay
preterm labor. (Haas, Caldwell et al. 2012). Activation of the Kv7 channels in
human myometrial smooth muscle at full term attenuated spontaneous myometrial
contractions (McCallum, Pierce et al. 2011), suggesting that Kv7 channel
activators may also represent a novel therapeutic approach to treat preterm labor.
The ability of Kv7 channel activators to relax vascular smooth muscle and Kv7
channel blockers to constrict vascular smooth muscle has made targeting Kv7
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channels located in the vasculature a rapidly expanding area of interest (Mackie
and Byron 2008, Jepps, Olesen et al. 2013, Stott, Jepps et al. 2014). These
channels may be considered novel targets for the treatment of a variety of vascular
disorders, including hypertension, pulmonary arterial hypertension, preeclampsia,
cerebral vasospasm and subarachnoid hemorrhage, coronary artery disease, and
hypotension (Haick and Byron 2016).
As detailed previously, asthma is a disease that is partially characterized by
reversible airway obstruction associated with exaggerated ASMC contraction and
airway narrowing in response to bronchoconstrictor stimuli. Although there are a
variety of treatments available, a surprisingly large portion of the asthmatic
population has poor control over their disease (Peters, Jones et al. 2007,
Chapman, Boulet et al. 2008). Despite the extensive efforts of researchers to
elucidate the role of airway smooth muscle in the pathophysiology of asthma and
identify new targets to treat the disease, no new pharmacological agents directed
towards targets in ASMCs have become available in recent years. Those that have
are often associated with unwanted side effects or poor selectivity for their targets
(Janssen 2009, Siddiqui, Redhu et al. 2013, Dowell, Lavoie et al. 2014). Kv7
channels are expressed in ASMCs across multiple species, their currents are
inhibited by bronchoconstrictor agonists, and activation of Kv7 channels relaxes
airways (Brueggemann, Kakad et al. 2012, Evseev, Semenov et al. 2013,
Brueggemann, Haick et al. 2014). The specific mechanism(s) responsible for
bronchoconstrictor agonist-induced inhibition of Kv7 channels are undefined and
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the potential of Kv7 channel activators to act as a novel treatment option for asthma
have yet to be fully explored, however the work in this dissertation aims to address
these knowledge gaps.

CHAPTER THREE
HYPOTHESIS AND AIMS
Main hypothesis: This project aims to test the hypothesis that Kv7 K+ channels in
airway smooth muscle are regulated by the bronchoconstrictor agonist histamine
in a PKC-dependent manner and that targeting these channels with clinically
available Kv7 channel activators represents a novel strategy for bronchodilatory
asthma therapy.

Specific Aim 1: To elucidate the mechanism by which the bronchoconstrictor
agonist histamine regulates Kv7 channels in airway smooth muscle.
Previous studies have revealed that Kv7 currents in guinea pig ASMCs are
inhibited upon treatment with the Gq–coupled receptor bronchoconstrictor agonists
histamine and methacholine (Brueggemann, Kakad et al. 2012). Silencing Kv7.5
expression in freshly isolated rat ASMCs abolished detectable Kv7 currents,
suggesting the functional importance of this particular subtype in mediating the
Kv7 currents in airway smooth muscle (data not shown). Treatment of freshly
isolated human trachealis smooth muscle with histamine or the PKC activator,
phorbol 12-myristate 13-acetate (PMA), resulted in the increased presence of
endogenous Kv7.5 channels in immunoprecipitates isolated using an antibody that
recognizes phosphorylated serine residues that fall within the PKC consensus
motif (Haick, Brueggemann et al. 2017), further highlighting the potential
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significance of this particular channel subtype. In vascular smooth muscle cells,
Gq-coupled receptor stimulation results in PKC-dependent phosphorylation of
Kv7.5 channels and inhibition of Kv7.5 currents (Brueggemann, Moran et al. 2007,
Mackie, Brueggemann et al. 2008, Brueggemann, Mackie et al. 2014). We
hypothesize that the Gq-coupled receptor agonist histamine phosphorylates Kv7.5
channels and inhibits Kv7.5 currents in a PKC-dependent manner in airway
smooth muscle as well.
ASMCs were isolated from human trachealis smooth muscle and cultured
at low passages (HTSMCs). Wild type (WT) or mutant FLAG-tagged human Kv7.5
(hKv7.5)

channels

were

overexpressed

using

an

adenoviral

vector.

Immunoprecipitation and western blotting approaches were used to examine the
phosphorylation status of WT and mutant hKv7.5 channels and whole cell
perforated patch clamp electrophysiology was used to measure WT and mutant
hKv7.5 currents in response to treatment with histamine or direct activation of PKC
with PMA.

Specific Aim 2: To determine the efficacy of Kv7 channel activators in attenuating
agonist-induced bronchoconstriction and explore their therapeutic potential for the
treatment of asthma.
In earlier studies, the Kv7 channel activator flupirtine attenuated histamineinduced constriction of human airways and the Kv7 channel inhibitor XE991
robustly constricted human airways (Brueggemann, Kakad et al. 2012). Precision
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cut lung slices (PCLS) prepared from Sprague-Dawley rats and discarded human
donor tissue were used to test the ability of the Kv7 channel activator retigabine to
attenuate agonist-induced airway constriction. PCLS prepared from tissue of a
guinea pig ovalbumin (OVA)-sensitization model of allergic asthma was used to
compare the ability of retigabine to reverse bronchoconstriction in normal and
asthmatic tissues. The ability of retigabine to alleviate the symptoms observed in
sensitized animals upon exposure to OVA was tested in vivo, as was the ability of
retigabine to attenuate bronchoconstrictor agonist-induced increases in respiratory
resistance.

CHAPTER FOUR
MATERIALS AND METHODS
Cell Culture.
HTSMCs were isolated as described previously (Janssen and Sims 1992,
Brueggemann,

Kakad

et

al.

2012)

from

de-identified

donor

tissues

(approved/exempted by the Loyola University Chicago Institutional Review Board
for the Protection of Human Subjects). Briefly, trachealis muscles were dissected
in ice-cold dissecting solution, containing (in mM): 145 NaCl, 4.7 KCl, 1.2
NaH2PO4, 1.2 MgSO4, 2 CaCl2_2H2O, 2 pyruvic acid, 0.02 EDTA dihydrate, 3
MOPS, 5 D-glucose, and 1% fatty acid-free BSA (pH adjusted to 7.4 with NaOH
on ice), cut into approximately 2 mm diameter strips, and immediately transferred
to ice-cold physiological saline solution (PSS), containing (in mM): 140 NaCl, 5.36
KCl, 0.34 Na2HPO4, 0.44 KH2PO4, 1.2 MgCl2, 0.05 CaCl2, 10 HEPES, and 10 Dglucose (pH adjusted to 7.2 with NaOH on ice, 298 mOsm/l). Strips were then
transferred into 37°C PSS (pH adjusted to 7.2 with NaOH at 37°C) supplemented
with BSA (1 mg/ml; fraction V, Roche Diagnostics USA), collagenase Type VIII
(950 units/ml; Sigma-Aldrich), papain (38 units/ml; Worthington), and DLdithiothreitol (1 mM; Sigma-Aldrich) for 45 min. Following enzymatic digestion, the
tissue strips were washed three to five times with ice-cold PSS and gently triturated
to release individual myocytes. Myocytes were cultured at low passages (2-9) in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine
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serum (Atlanta Biologicals), antibiotics and antimycotics (Sigma Aldrich) at 37°C
under 5% CO2.
Adenoviral infection. For overexpression of WT or mutant (S441A or
T505A) human Kv7.5 (hKv7.5) channels, HTSMCs were infected at confluence
with an adenoviral expression vector (Adv-hKCNQ5-FLAG-WT, Adv-hKCNQ5FLAG-S441A, or Adv-hKCNQ5-FLAG-T505A) at a multiplicity of infection (MOI) of
100 for a minimum of 6 days prior to experimentation. Expression was confirmed
by detection of green fluorescent protein (GFP) fluorescence (GFP is coexpressed via the same hKCNQ5-FLAG adenoviral vector) and by western blot
analysis.
Retroviral infection. For knockdown of PKCα expression, a retroviral
vector driving expression of a PKCα short hairpin RNA (shRNA) was employed
essentially as described previously (Denning, Wang et al. 2002). HTSMCs were
plated in 6 well plates at 105 cells per well. Approximately 24 hr later, shControl or
shPKCα retroviral supernatants supplemented with 4 µg/ml hexadimethrine
bromide (Sigma-Aldrich) were added to the appropriate wells and plates were spun
at 300 x g for 1 hr at 32°C. Viral supernatants were immediately replaced with fresh
culture medium. For some experiments this process was repeated after
approximately 6 hr to assure adequate infection. The following day, cells were
washed twice with phosphate-buffered saline and then incubated with media
containing 0.5 µg/ml puromycin dihydrochloride (EMD Millipore) for selection
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purposes. Effective knockdown of shPKCα expression was confirmed by western
blot analysis.
Constructs used for infections. An adenoviral vector to express human
KCNQ5-WT (Adv-hKCNQ5-FLAG-WT, with a FLAG epitope on the amino
terminus), human KCNQ5-S441A (Adv-hKCNQ5-FLAG-S441A, with a FLAG
epitope on the amino terminus), or human KCNQ5-T505A (Adv-hKCNQ5-FLAGT505A, with a FLAG epitope on the amino terminus) were created previously using
the AdEasy Adenoviral Vector System (Stratagene). Retroviral vectors to express
shRNA targeting human PKCα (shPKCα, AGGCUGAGGUUGCUGAUGA) or
shRNA targeting a sequence not found in the human genome (shControl,
GCGCGCTTTGTAGGATTCG)

were

created

previously

using

the

pSUPER.retro.puro vector system (OligoEngine) (Jerome-Morais, Rahn et al.
2009).

Electrophysiology.
Whole-cell membrane currents in single HTSMCs overexpressing hKv7.5
channels (infected with Adv-hKCNQ5-FLAG WT, S441A or T505A for a minimum
of 6 days) were measured using perforated patch configurations under voltageclamp conditions. Cells were trypsinized and allowed to attach to glass coverslips
for 15-20 min at 37°C. Experiments were performed at room temperature while
being continuously perfused with an external bath solution containing (in mM): 5
KCl, 130 NaCl, 10 HEPES, 2 CaCl2, 1.2 MgCl2, 5 D-glucose (pH 7.3, 298 mOsm).
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Standard internal (pipette) solution contained (in mM): 110 potassium gluconate,
30 KCl, 5 HEPES, 1 K2EGTA (pH 7.2, 298 mOsm) and was supplemented with
120 μg/ml Amphotericin B immediately prior to experimentation for patch
perforation.
Voltage-clamp command voltages were generated using an Axopatch 200B
amplifier (Molecular Devices) under control of pCLAMP 10 (Molecular Devices).
Series resistances after amphotericin perforation were 20-35 MΩ and were
compensated by 40%. Whole-cell currents were digitized at 2 kHz and filtered at 1
kHz.
Exogenous hKv7.5 currents were recorded using a 5 sec voltage step
protocol from a -74mV holding potential to test voltages ranging from -124 mV to 4 mV, followed by a 1 sec step to -120 mV. The currents recorded during the last
1 sec of recording time for each voltage step were averaged and normalized by
cell capacitance to obtain end-pulse steady-state hKv7.5 currents. The time course
of drug application was recorded with repetitive 5 sec steps from -74 to -20 mV
every 5 sec.

Immunoprecipitation and Western Blot Analysis.
HTSMCs were infected with Adv-hKCNQ5-FLAG-WT or Adv-hKCNQ5FLAG-S441A at 100 MOI for 6 days and serum deprived overnight prior to
experimentation. On the day of the experiment, HTSMCs were incubated for 3 hr
at room temperature in modified Kreb’s buffer (mKreb’s) containing (in mM): 5.9
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KCl, 135 NaCl, 11.6 HEPES, 1.5 CaCl2, 1.2 MgCl2, 11.5 glucose (pH 7.3) prior to
treatment. Immediately following treatment, cells were lysed with ice-cold lysis
buffer containing 100 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate,
30 mM sodium pyrophosphate, 5 mM β-glycerophosphate, 20 mM HEPES (pH
7.4)

and

supplemented

with

10

µg/ml

leupeptin

(Bachem),

0.5

mM

phenylmethanesulfonyl fluoride (Sigma-Aldrich) or Pefabloc (Acros Organics), 10
µg/ml aprotinin (Sigma-Aldrich) and 500 µM Na3VO4. Equal protein concentrations
of cell lysates (350-500 µg) were incubated overnight at 4C with 4 µg of anti-FLAG
antibody (Sigma-Aldrich, F7425). 20 µl of Dynabeads® Protein G (Invitrogen, Life
Technologies) were added to antibody-containing lysates and incubated for 2 hr at
4C. The beads were washed and immune complexes were eluted with 1X
Laemmli sample buffer (5% SDS, 10% glycerol, 50 mM Tris, pH 6.8, 0.01%
bromophenol blue, 10% β-mercaptoethanol, 100 mM dithiothreitol), heated for 5
min at 97C and separated by SDS-PAGE on 10% acrylamide gels. Proteins were
transferred to polyvinylidene fluoride membranes, blocked in 5% nonfat milk, and
probed with anti-phosphoserine PKC substrate antibody (rabbit polyclonal 1:1000,
Cell Signaling Technology, 2261) overnight at 4°C. Membranes were washed and
then probed with anti-rabbit IgG HRP-conjugated secondary antibody (1:10,000,
Thermo Scientific, 31460) for 1 hr at room temperature. For immunoprecipitation
(IP) loading controls, 25 µg of protein from lysates for each IP sample were run on
separate 10% acrylamide gels or original membranes were quenched with 1%
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sodium azide and then re-probed with anti-FLAG M2 peroxidase conjugate (mouse
monoclonal 1:10,000, Sigma-Aldrich, A8592) for 1 hr at room temperature.
To confirm PKCα knockdown, 25 µg of protein from lysates for each
experiment were run on separate 10% acrylamide gels, probed with anti-PKCα
(mouse monoclonal 1:1000, BD Biosciences, 610108) overnight at 4C, washed,
and then probed with anti-mouse IgG HRP-conjugated secondary antibody
(1:10,000, Thermo Scientific, 31430) for 1 hr at room temperature. For loading
controls, membranes were incubated with anti-GAPDH (mouse monoclonal
1:1000, Novus Biologicals, NB300-221) for 1 hr at room temperature, washed, and
then probed with anti-mouse IgG HRP-conjugated secondary antibody for 1 hr at
room temperature.
Western blot results were visualized using enhanced chemiluminescence
(Optiblot ECL Detect Kit, abcam or Amersham ECL Prime Western Blotting
Detection Reagent, GE Healthcare Life Sciences). ImageJ software was used for
densitometry analysis.

[Ca2+]cyt Measurements with Fura-2.
Confluent monolayers of cultured HTSMCs in six-well plates were serum
deprived overnight prior to experimentation. On the day of experiment, cells were
washed twice with mKreb’s buffer at room temperature and background
fluorescence was recorded using a Biotek Synergy HT plate reader (340 and 380
nm excitation, 510 nm emission) and Gen5 software (BioTek Instruments,
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Winooski, VT). Cells were then incubated in mKreb’s plus 1μM fura-2
acetoxymethyl ester (Invitrogen), 0.1% bovine serum albumin, and 0.02% Pluronic
F127 detergent for 90 min at room temperature in the dark. After this fura-2 loading
period, cells were washed twice with mKreb’s and incubated for an additional 60
min in mKreb’s at room temperature in the dark. Changes in [Ca2+]cyt in response
to treatments were estimated based on fura-2 fluorescence measured at 510 nm
with alternating excitation at 340 and 380 nm wavelengths. Background values
were subtracted from each wavelength prior to calculating the 340/380
fluorescence ratio. Values were normalized to the average fluorescence ratio
recorded during the 2-min period prior to treatment. Sustained elevation of [Ca2+]cyt
in response to treatment was evaluated based on the average fluorescence ratio
recorded during the 5-min period beginning 10 min after initiation of treatment.
Each “n” is the average of 3-6 wells.

Immunofluorescence.
Freshly isolated HTSMCs and HTSMC at passages 2, 4, 6, and 8 were
plated on 12 mm coverslips 1 day prior to fixing. The cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline and permeabilized with 0.5%
Triton X 100 in phosphate-buffered saline. Coverslips were incubated in Image-iT
signal enhancer (Thermo Fischer Scientific) prior to blocking. A coverslip from
each passage was incubated with polyclonal goat anti-SM22α (abcam, ab10135)
or polyclonal rabbit anti-KCNQ5 (abcam, ab96707) antibodies at 1:100 dilution at
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4°C overnight. Alexa Fluor® 488 rabbit anti-goat IgG or Alexa Fluor® 594 goat antirabbit at 1:400 dilution were used as secondary antibodies. Each coverslip was
treated with SlowFade Antifade Equilibration Buffer (Molecular Probes, Eugene,
OR) and ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific)
prior to mounting on a glass slide. Cell images were acquired with an Olympus
1X71 inverted epifluorescence microscope, a Hamamatsu Orca 12-bit digital
camera, and Simple PCI software. SM22α images were captured with a 0.1 second
exposure using a 505 nm LP dichroic filter (480/40 nm excitation filter, 535/50 nm
emission). Kv7.5 images were captured with a 0.5 second exposure using a 564
nm LP dichroic filter (535/50 nm excitation filter, 620/60 nm emission). DAPI
images were captured with a 0.2 second exposure using a 400 nm LP dichroic
filter (340 & 380 nm filters in Sutter DG-4). Coverslips incubated without primary
antibody had no detectable fluorescence at the wavelength, gain, or exposure
settings used.

Mass Spectrometry.
HTSMCs were grown to confluence on 150 mm dishes and infected at 100
MOI with Adv-hKCNQ5-FLAG-WT or Adv-hKCNQ5-FLAG-S441A or at 500 MOI
with Adv-hKCNQ5-FLAG-T505A for 6 days and serum deprived overnight prior to
experimentation. On the day of the experiment, HTSMCs were incubated for 3 hr
at room temperature in mKreb’s prior to treatment. Immediately following
treatment, cells were lysed with ice-cold lysis buffer. Equal protein concentrations
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of cell lysates (1.1 mg) were incubated overnight at 4C with 4 µg of anti-FLAG
antibody. 20 µl of Dynabeads® Protein G were added to antibody-containing
lysates and incubated for 2 hr at 4C. The beads were washed and immune
complexes were eluted with 1X Laemmli sample buffer, heated for 5 min at 97C,
and stored at -20°C until further use by Dr. Kolla Kirstjansdottir at Midwestern
University, Downers Grove, IL.
Enzymatic digestion. Samples were separated by SDS-PAGE on 10%
acrylamide gels. Gel was stained with Coomassie Brilliant Blue to identify the
bands for analysis. These bands were excised using a razor blade and cut into
approximately 1 mm3 pieces. Each piece was washed in water and destained
using 100 mM ammonium bicarbonate (NH4HCO3, pH 7.5) in 50% acetronitrile.
The reduction step was performed by the addition of 100 µl 50 mM NH4HCO3 (pH
7.5) and 10 µl 10 mM Tris(2-carboxyethyl)phosphine HCl for 30 min at 37°C.
Proteins were alkylated by adding 100 µl 50 mM iodoacetamide for 30 min at 20°C
in the dark. The gel sections were then washed in water, then acetonitrile, and
dried in a SpeedVac.
Samples were digested with either endoproteinase Glu-C (EndoQ) or
endoproteinase Lys-C (EndoK). EndoQ digestion was carried out with 160 ng
Mass Spectrometry Grade Glu-C enzyme (Thermo #90054) in 50 mM NH4HCO3
(pH 7.5) overnight at 37°C. EndoK digestion was carried out with 160 ng Mass
Spectrometry Grade Lys-C enzyme (Thermo #Q12057892) in 50 mM NH4HCO3
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(pH 7.5) overnight at 37°C. Peptides were extracted with 5% formic acid, vacuum
dried, and sent to Don Wolfgeher at the University of Chicago (Chicago, IL).
High Performance Liquid Chromatography for mass spectrometry.
Samples were then re-suspended Burdick & Jackson HPLC-grade water
containing 0.2% formic acid (Fluka), 0.1% TFA (Pierce), and 0.002% Zwittergent
3–16 (Calbiochem), a sulfobetaine detergent (MH+ at 392, and in-source dimer
[2 M + H+] at 783, and some minor impurities of Zwittergent 3–12 seen as MH+ at
336; peaks that will be at the end of the chromatograms). Peptide samples were
loaded to a 0.25 μl C8 OptiPak trapping cartridge custom-packed with Michrom
Magic (Optimize Technologies) C8, washed, then switched in-line with a 20 cm by
75 μm C18 packed spray tip nano column packed with Michrom Magic C18AQ, for
a 2-step gradient. Mobile phase A was water/acetonitrile/formic acid (98/2/0.2) and
mobile phase B was acetonitrile/isopropanol/water/formic acid (80/10/10/0.2). A
flow rate of 350 nl/min was used during a 90 min, 2-step LC gradient: 60 min from
5% B to 50% B, 10 min 50%–95% B, 10 min hold at 95% B, and then back to
starting conditions and re-equilibrated.
Liquid Chromatography-MS/MS analysis. Samples were analyzed via
electrospray tandem mass spectrometry (LC–MS/MS) on a Thermo Q-Exactive
Orbitrap mass spectrometer. A 70,000 RP survey scan in profile mode, m/z 360–
2000 Da, with lockmasses was used, followed by 20 MSMS HCD fragmentation
scans at 17,500 resolution on doubly and triply charged precursors. Single charged
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ions were excluded, and ions selected for MS/MS were placed on an exclusion list
for 60 sec.
Tandem mass spectra were extracted, charge state deconvoluted and
deisotoped by Proteowizard MSconvert version 3.0.9134. Mascot (Matrix Science,
London, UK; version 2.3.02) and X! Tandem (The GPM, thegpm.org; version
CYCLONE

(2010.12.01.1))

were

160107_SPROT_Human_Iso_UP000005640

set

up

database

to

search

(1-07-2016,

the
92013

entries) assuming the digestion enzymes Lys-C of Glu-C (V8). Fragment search
specifications include an ion mass tolerance of 0.40 Da and a parent ion tolerance
of 10.0 PPM. Fixed modification settings included Carbamidomethyl of cysteine.
Variable modification settings included de-amidated of asparagine and glutamine,
oxidation of methionine, formyl of the n-terminus and phospho of serine, threonine
and tyrosine in Mascot and Glu->pyro-Glu of the n-terminus, ammonia-loss of the
n-terminus, gln->pyro-Glu of the n-terminus, de-amidated of asparagine and
glutamine, oxidation of methionine, formyl of the n-terminus and phospho of serine,
threonine and tyrosine in X! Tandem.
Criteria for protein identification. Validation of MS/MS based peptide and
protein identifications was made using Scaffold (version Scaffold_4.7.5, Proteome
Software Inc., Portland, OR). Peptide identifications were accepted if they could
be established at greater than 87.0% probability to achieve a false discovery rate
less than 1.0%. The Mascot peptide probabilities were assigned by the Scaffold
Local false discovery rate algorithm while the X! Tandem peptide probabilities were
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assigned by the Peptide Prophet algorithm (Keller, Nesvizhskii et al. 2002) with
Scaffold delta-mass correction. The criteria for acceptable protein identifications
included containing at least 2 identified peptides and a greater than 6.0%
probability to achieve a false discovery rate less than 1.0%, with the probabilities
being assigned by the Protein Prophet algorithm (Nesvizhskii, Keller et al. 2003).
Proteins that could not be differentiated by MS/MS analysis due to similar peptides
were grouped to satisfy the principles of parsimony and proteins that shared
significant peptide evidence were grouped into clusters. Proteins were annotated
with gene ontology terms from NCBI (downloaded Mar 10, 2016 (Ashburner, Ball
et al. 2000)).
Post-translational modification site localization. Post-translational
modification sites were annotated using Scaffold Post-Translational Modification
(version Scaffold_4.4.6, Proteome Software, Portland, Oregon, USA). The site
localization algorithm developed by Beausoleil et al. (Beausoleil, Villen et al. 2006)
was used to re-analyze MS/MS spectra identified as modified peptides and
develop a score that is calculated to assess the level of confidence in each PTM
localization. Localization probabilities for all peptides containing each identified
post-translational modification site are combined to obtain the best estimated
probability that a post-modified is present at that particular site.
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Animal Welfare and Housing.
Male Sprague-Dawley rats were purchased from Harlan Laboratories
(Indianapolis, IN). Animals were housed in pairs in standard cages and fed with
standard chow in a 12 hr dark-light cycle. All procedures were approved by the
Institutional Animal Care and Use Committee, Loyola University Medical Center,
Maywood, IL and were executed in accordance with the National Academy of
Sciences Guide for the Care and Use of Laboratory Animals.
Male Hartley guinea pigs were purchased from Harlan Laboratories or
Charles River Laboratories (Skokie, IL). Animals were housed in pairs in standard
cages and fed with standard chow in a 12 hr dark-light cycle. All procedures were
approved by the Institutional Animal Care and Use Committee (Loyola University
Medical Center, Maywood, IL or Edward Hines, Jr. Veterans Affairs Hospital,
Hines, IL) and were executed in accordance with the National Academy of
Science’s Guide for the Care and Use of Laboratory Animals.

Guinea Pig Sensitization Model.
Male Hartley guinea pigs, 250-350g, were given 3 intraperitoneal injections
of OVA (100 µg OVA and 100 mg aluminum hydroxide in 1 ml saline) or saline
alone (control) on days 1, 3 and 5. Following a 2 week sensitization period, on day
19 the animals were exposed to a fine mist of OVA (5 mg/ml) in a cylindrical
plexiglass chamber for 30 min. Control guinea pigs did not display any symptoms.
OVA-sensitized guinea pigs displayed symptoms such as chewing, rapid and
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labored breathing, and gasping within 5-10 min, followed by more severe
symptoms, including coughing, cyanosis, and convulsions, at approximately 15
min into the challenge prompting their removal from the chamber and cessation of
the challenge. This procedure was repeated on days 20 and 21. Tissues were
collected post-euthanasia for study on day 22.
Tissue collection. Guinea pigs were euthanized by intraperitoneal injection
of sodium pentobarbital or Euthasol®. The trachea was cut and cannulated with a
3 mm outer-diameter polypropylene-barbed tubing connector connected to 3-way
stopcock and two 10 mL syringes. The lungs and heart were excised and placed
into a modified Hank’s balanced salt solution (mHBSS) containing (in mM): NaCl
137.9, KCl 5.33, CaCl2 1.26, MgCl2 0.49, MgSO4 0.41, HEPES 20, KH2PO4 0.44,
Na2HPO4 0.34, D-glucose 5 (pH 7.4 at 37°C, 298–300 mOsm) that had been
preheated to 37°C.
Precision cut lung slices. Approximately 5 mL of air was withdrawn from
the lungs to deflate them followed by inflation of the lungs with 20-25 mL of 2%
low-melting temperature agarose in mHBSS 37°C supplemented with 1 μM
isoproterenol. 5 mL of air was injected back into the lungs following inflation with
agarose and tissue was cooled in mHBSS 4°C (pH 7.4 at 4°C, 298-300 mOsm) for
30 min to allow for agarose solidification. Lobes were then separated, trimmed
perpendicular to the bronchus, and sliced 500 μm thick using a Leica VT 1200S
vibratome (Leica Microsystems, Buffalo Grove, IL). Lung slices were incubated in
serum-free tissue culture serum-free F-12/DMEM medium supplemented with
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insulin-transferrin-selenium (Sigma-Aldrich), antibiotics and antimycotics (SigmaAldrich), and 1 μM isoproterenol for 4-6 hours and then changed to medium with
no isoproterenol overnight. The slices were kept at 37°C in 5% CO2 and used for
up to 4 days after preparation.
If guinea pig lung slices are taken out of media immediately prior to
experimentation, airways often go through a slow contraction and relaxation cycle
that lasts approximately 4-6 hours in which the airways will be nonresponsive to
bronchoconstrictor agonist treatment. Therefore, slices that contained round, open
airways with beating cilia, and an intact airway wall and surrounding parenchyma
attachments were selected and incubated overnight at room temperature in control
medium containing (in mM) 140 NaCl, 5.36 KCl, 1.2 MgCl2, 2 CaCl2, 10 HEPES,
10 D-glucose (pH 7.3, 298 mOsm/l) so as to avoid the contraction-relaxation cycle
and to promote a more stable airway diameter for experimentation.
To measure airway area, a lung slice was mounted in a perfusion chamber
located on the stage of an Olympus IX-71 inverted microscope and a single airway
was visualized using a 5X or 10X objective. All experiments were completed at
room temperature. The lung slice was perfused with control medium (~1 drop/sec)
for 20 minutes, or until a stable baseline area was achieved for 20 minutes, prior
to perfusion of control medium containing drug. Images were captured every 5 sec
with a Hamamatsu Orca 12-bit digital camera and luminal airway area was
determined using Simple PCI software.
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Human Precision Cut Lung Slices.
Human lung tissue not suitable for transplantation was obtained from Dr.
Jeffrey Schwartz of the Department of Thoracic and Cardiovascular Surgery at
Loyola University Chicago or from Dr. Julian Solway at the University of Chicago.
Tissue was infused with injections of 2% low-melting temperature agarose in
mHBSS at 37°C and cooled in mHBSS 4°C to allow for solidification of agarose.
Once solidified, tissue was sliced 0.5-1 mm thick perpendicular to airways using a
Leica VT 1200S vibratome. Lung slices were incubated in serum-free tissue culture
F-12/DMEM medium supplemented with insulin-transferrin-selenium (SigmaAldrich) and antibiotics and antimycotics (Sigma-Aldrich). The slices were kept at
37°C in 5% CO2 and used for up to 4 days after preparation.
To measure airway area, a lung slice was mounted in a perfusion chamber
located on the stage of an Olympus IX-71 inverted microscope and a single airway
was visualized using a 5X or 10X objective. All experiments were completed at
room temperature. The lung slice was perfused with control medium (~1 drop/sec)
for 20 minutes, or until a stable baseline area was achieved for 20 minutes, prior
to perfusion of control medium containing drug. Images were captured every 5 sec
with a Hamamatsu Orca 12-bit digital camera and luminal airway area was
determined using Simple PCI software.
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Guinea Pig flexiVent Optimization Experiments.
Naïve male Hartley guinea pigs (250-550 g) were weighed and anesthetized
with intraperitoneal injection of Inactin® (thiobutabarbital, 300-400 mg/kg, given
100 mg/kg initially followed by 50 mg/kg increments every 15 minutes until the
animal is fully anesthetized). The trachea was cannulated the animal was
ventilated using a computer-controlled small animal ventilator (flexiVent, SCIREQ,
Montréal, QC, Canada) at a rate of 60 breaths/minute and a tidal volume of 5 ml/kg.
Respiratory resistance was measured using the flexiVent “snapshot” maneuver (1
second duration, 1 Hz frequency) and Newtonian resistance, tissue dampening,
and tissue elastance were measured using the flexiVent “quick prime-6” maneuver
(6 second duration, 1-20.5 Hz frequency) using flexiWare software (flexiVent,
SCIREQ, Montréal, QC, Canada). Once a stable baseline resistance value was
obtained, the animals were given doses of histamine or methacholine using either
an intravenous (i.v.) catheter or an in-line computer-controlled Aeroneb Lab
nebulizer at approximately 5-minute intervals. For i.v. administration, 100 µl of
each concentration in saline was injected followed by a 50 µl heparinized saline
flush (50 U/ml). For nebulized administration, 200 µl of each concentration in water
was pipetted onto the nebulizer. After each administration of bronchoconstrictor,
the peak resistance value was recorded using a series of “snapshot” and “quick
prime-6” maneuvers for 5 minutes prior to the next administration. At the end of
each experiment, animals were euthanized via intraperitoneal injection of
Euthasol® Euthanasia Solution.
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Statistics.
Data are expressed as mean ± standard error of the mean (S.E.). SigmaStat
(Systat Software, Inc.) was used for all statistical analyses. Independent t-test or
the t-test followed by the Mann-Whitney Rank Sum test was used for comparisons
between two independent groups. Paired Student’s t-test was used for
comparisons of parameters measured before and after treatments. Comparisons
between more than two independent treatment groups were evaluated by analysis
of variance (ANOVA) followed by the Holm-Sidak post hoc test. Comparisons
among multiple treatments of the same subject (cell or airway) were evaluated by
repeated measures ANOVA followed by the Holm-Sidak post hoc test. Differences
associated with p values ≤ 0.05 were considered statistically significant.

CHAPTER FIVE
RESULTS
Cultured HTSMCs Retain SM22α Expression.
Culturing ASMCs to study the regulation of airway smooth muscle
responses at the cellular level, including cell signaling and regulation of protein
expression, is a method that has been in place for decades (Hall and Kotlikoff
1995). We considered it necessary to confirm that the smooth muscle phenotypes
persisted upon the culturing of HTSMCs by using immunofluorescence to confirm
the expression of SM22α, a protein that is largely specific for smooth muscle (LeesMiller, Heeley et al. 1987), in freshly isolated HTSMCs cultured to passage 8
(Figure 2).

Histamine Increases [Ca2+]cyt in Cultured HTSMCs.
As described in detail in chapter 2, bronchoconstrictor agonists induce a
biphasic increase in [Ca2+]cyt that is necessary for ASMC contraction. To confirm
that the cultured HTSMCs retain this Ca2+ response to the bronchoconstrictor
histamine, fura-2 fluorescence techniques were used to monitor changes in
[Ca2+]cyt. Treatment of cultured HTMSCs with 1 µM histamine resulted in a 1.445fold increase in sustained [Ca2+]cyt over initial control levels (Figure 3B).
To examine the involvement of L-type VSCCs in the sustained increase in
[Ca2+]cyt, we simultaneously treated cells with histamine (1 µM) and the L-type
56
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Figure 2. Cultured HTSMCs express SM22α through passage 8. The top row
of panels are representative images of freshly isolated (far left) or cultured
HTSMCs (passages 2, 4, 6, and 8) expression of SM22α. The second row of
panels are the same field, but showing DAPI stained nuclei of the cells imaged in
the top row. The third row of panels are representative images of the minus primary
SM22α antibody control. The fourth row of panels are the same field, but showing
DAPI stained nuclei of the cells shown in the third row.
VSCC blocker verapamil (10 µM). The increase in sustained [Ca2+]cyt was
significantly smaller (1.209-fold over initial control levels, Figure 3B) than observed
with histamine treatment alone, confirming a role for L-type VSCC in Ca2+ influx
following bronchoconstrictor agonist treatment.
It is also worth noting that the Kv7 channel blocker XE991 (10 µM) induced
a small but significant increase in sustained [Ca2+]cyt in cultured HTSMCs (Figure
3C).
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Figure 3. Histamine induces L-type VSCC-dependent increases in [Ca2+]cyt in
cultured HTSMCs. (A) Averaged time courses of [Ca2+]cyt following treatment of
cultured HTSMCs with histamine (1 µM, closed circles, n=15) or histamine plus
verapamil (10 µM, open circles, n=14). (B) Summary of 5 experiments (triplicate
wells). Data shows average [Ca2+]cyt for the final 10-15 minutes of treatment
(“sustained” [Ca2+]cyt increases) with histamine (black bar) or histamine plus
verapamil (white bar). (C) Summary of 3 experiments (triplicate wells). Data shows
average [Ca2+]cyt for the final 10-15 minutes of treatment (“sustained” [Ca2+]cyt
increases) with Kv7 channel blocker XE991 (10 µM, dark grey bar). NOTE: All
values were normalized to the average F340/380 values recorded during the 2
minutes prior to treatment. *, significant difference from indicated groups, p < 0.05,
one way ANOVA followed by Holm-Sidak post hoc test multiple comparisons
among all groups. #, significantly different from control, p < 0.05, paired t-test.
Activation of PKC Suppresses hKv7.5 Currents in Cultured HTSMCs.
HTSMCs were cultured at low passages and used as an expression system
to study the regulation of WT or mutant hKv7.5 channels. Similar to previous
observations our laboratory has made regarding endogenous Kv7 currents
(Brueggemann, Kakad et al. 2012, Haick, Brueggemann et al. 2017), in cultured
HTSMCs overexpressing WT hKv7.5 channels, the application of histamine (1 μM)
significantly suppressed hKv7.5 currents (by 34.4 ± 6.2% at -20 mV, Figure 4C)
approximately 1-2 minutes following the start of histamine treatment (Figure 4B).
If
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chlorpheniramine (30 μM) before being treated with histamine, no hKv7.5 current
inhibition was observed (Figure 4D). The vehicle for chlorpheniramine did not have
an effect on hKv7.5 currents (data not shown). Pretreatment with the PKC inhibitor
Ro-31-8220 (3 μM) for 1 hour prior to histamine treatment significantly attenuated
the amount of histamine-induced hKv7.5 suppression that was observed (9.66 ±
3% at -20 mV, Figure 5) compared to treatment with histamine alone (by 34.4 ±
6.2% at -20 mV, Figure 4C). The direct activation of PKC with PMA (1 nM, Figure
6A), also induced significant suppression of hKv7.5 currents (by 75.5 ± 7.6% and
10.2 ± 4.9%, respectively, at -20 mV). No current suppression was observed
following treatment with PMA’s inactive analog, 4α-PMA (1 nM, Figure 6B).

Activation of PKC Induces Phosphorylation of hKv7.5 Channels in Cultured
HTSMCs.
We next wanted to test the effects of PKC activation with either histamine
or PMA on hKv7.5 channel phosphorylation. A FLAG antibody was used to
immunoprecipitate FLAG-tagged hKv7.5 channels following no treatment,
treatment with histamine (1 µM) for 10 minutes, or treatment with PMA (1 nM) for
30 minutes. An antibody that recognizes phosphorylated serine residues that fall
within a specific PKC consensus motif (anti-phosphoserine PKC substrate) was
used to examine hKv7.5 channel phosphorylation. This antibody recognizes
phosphorylated serine residues that fall within the conventional PKC consensus
motif: arginine or lysine is found at positions -2 and +2, while a hydrophobic amino
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Figure 4. Histamine inhibits hKv7.5 currents in cultured HTSMCs. (A)
Representative traces of hKv7.5 currents recorded with a voltage-step protocol
(see materials and methods) in one cultured HTSMC, i, before and, ii, after
treatment with 1 µM histamine (capacitance = 100 pF). (B) Averaged time course
of histamine-induced hKv7.5 current inhibition at -20 mV in cultured HTSMCs
(n=5). Normalized to average current 5 minutes prior to treatment with histamine.
(C) Current-voltage (I-V) curves of steady state currents through hKv7.5 channels
recorded in cultured HTSMCs before (filled circles) and after treatment with
histamine (1 µM, open circles, n=6). (D) I-V curves of steady state currents through
hKv7.5 channels recorded in cultured HTSMCs before (filled circles) treatment with
chlorpheniramine (30 µM, open circles) and then histamine (1 µM) in the continued
presence of chlorpheniramine (filled triangles, n = 4). *, significantly different from
control, p < 0.05, paired t-test.
acid (phenylalanine, isoleucine, leucine, valine, or tyrosine) is commonly found at
the +1 position.
Indirect activation of PKC with histamine and direct activation of PKC with
PMA both resulted in a significant increase in hKv7.5 phosphorylation compared
to untreated control samples (1.82 ± 0.28 -fold and 1.73 ± 0.3 -fold greater than
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Figure 5. Histamine-induced inhibition of hKv7.5 currents in cultured
HTSMCs is dependent on PKC. (A) I-V curves of stead state currents through
hKv7.5 channels recorded in cultured HTSMCs pretreated with for 1 hour with Ro31-8220 (3 µM) before (filled circles) and after histamine (1 µM, open circles)
treatment (n=5). (B) Summarized data shows average hKv7.5 current at -20 mV
under control conditions (black bar), following treatment with histamine (1 µM, grey
bar, n=6), or after 1 hour Ro-31-8220 (3 µM) pretreatment prior to histamine
treatment (red bar, n=5). *, significantly different from control, p < 0.05, paired ttest. ‡, significant difference from indicated groups, p < 0.05, one way ANOVA
followed by Holm-Sidak post hoc test, with multiple comparisons among all groups.
untreated control, respectively, Figure 7C). Pretreatment with the PKC inhibitor
Ro-31-8220 (1 hour, 1, 3, and 10 μM) significantly attenuated histamine-induced
phosphorylation of hKv7.5 (Figure 7D).
In retrospect, a time course examining the phosphorylation status of hKv7.5
following histamine treatment should have been completed in order to determine
the optimal time point for experimentation. Before completing the additional
experiments to examine the PKC isoform or the amino acid residues involved in
histamine-induced phosphorylation of hKv7.5, we examined the level of hKv7.5
phosphorylation following 30 seconds, and 1, 2, 5, 10, or 30 minutes of histamine,
or vehicle, treatment (Figure 8). Maximal channel phosphorylation occurred within
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the first two minutes of treatment (3.36 ± 1.52 -fold, 2.54 ± 0.97 -fold, and 2.47 ±
0.58 -fold greater than untreated control, at 30 seconds, 1 minute, and 2 minutes,
respectively) and eventually declined to near control levels by 10 and 30 minutes
(1.27 ± 0.19 –fold and 1.39 ± 0.39 –fold greater than untreated control,
respectively, Figure 8). The initial increase in hKv7.5 channel phosphorylation
corresponds with the time course observed for histamine-induced hKv7.5 current
inhibition (Figure 4B). The 1 minute time point was selected for the remaining
experiments.

PKCα is Necessary for the Regulation of hKv7.5 Currents by Histamine, but
not for Channel Phosphorylation.
PKCα is known to be activated following the activation of the H1 histamine
receptor (Eto, Kitazawa et al. 2001, Megson, Walker et al. 2001, Rimessi, Rizzuto
et al. 2007) and studies completed in A7r5 cells and rat mesenteric artery smooth
muscle cells have suggested that the activation of PKCα is sufficient to suppress
Kv7 currents in vascular smooth muscle (Brueggemann, Mackie et al. 2014). In
order to determine if histamine-induced suppression of hKv7.5 currents in ASMCs
is mediated by PKCα, we infected cultured HTSMCs with a retroviral vector that
drives the expression of shRNA against PKCα (shPKCα), or control vector
(shControl), before overexpressing hKv7.5 channels as we had done for the
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Figure 6. PMA, but not 4α-PMA, inhibits hKv7.5 currents in cultured HTSMCs.
(A) I-V curves of steady state currents through hKv7.5 channels recorded in
cultured HTSMCs before (filled circles) and after treatment with PMA (1 nM, open
circles, n=4). (B) I-V curves of steady state currents through hKv7.5 channels
recorded in cultured HTSMCs before (filled circles) and after treatment with 4αPMA (1 nM, open circles, n=3). *, significantly different from control, p < 0.05,
paired t-test.
studies described above. PKCα knockdown was confirmed by western blotting
(Figure 10A). There was no histamine-induced suppression of hKv7.5 currents in
cells that lacked PKCα (Figure 9A). Cells that lacked PKCα also had a significantly
smaller histamine-induced increase in sustained [Ca2+]cyt compared to control cells
(Figure 9D). Unexpectedly, knocking down PKCα did not prevent the significant
increase in histamine-induced phosphorylation of hKv7.5 channels on serine
residues located in the PKC consensus motif (1.48 ± 0.23 fold above untreated
control, Figure 10).
Threonine Residue 505 may be Necessary for the Regulation of hKv7.5
Currents by Histamine.
Serine residue 541 in rat Kv7.2 is phosphorylated by PKC and required for
channel inhibition by acetylcholine (Hoshi, Zhang et al. 2003). This residue
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Figure 7. PKC activation promotes hKv7.5 channel phosphorylation in
HTSMCs. (A) Representative western blot of FLAG immunoprecipitates from
cultured HTSMCs overexpressing FLAG-hKv7.5 channels that were left untreated,
treated with histamine (1 µM, 10 minutes), or treated with PMA (1 nM, 30 minutes)
probed with an anti-phosphoserine PKC substrate antibody (top). Whole cell
lysates (50 µg) were run separately and probed with an anti-FLAG antibody to
serve as a loading control (bottom). (B) Representative western blot of
immunoprecipiates from cultured HTSMCs overexpressing FLAG-hKv7.5
channels that were left untreated, treated with histamine (1 µM, 10 minutes), or
pretreated with Ro-31-8220 (1, 3, or 10 µM, 1 hour) prior to histamine treatment
probed with an anti-phosphoserine PKC substrate antibody (top). Whole cell
lysates (50 µg) were run separately and probed with an anti-FLAG antibody to
serve as a loading control (bottom). (C) Densitometry summarized from 11
experiments depicted in A. (D) Densitometry summarized from 5 different
experiments depicted in B. *, significantly different from control, p < 0.05, one-way
ANOVA followed by Holm-Sidak post hoc test multiple comparisons versus control
group. #, significantly different from histamine group, p < 0.05, one-way ANOVA
followed by Holm-Sidak post hoc test multiple comparisons versus histamine
group.
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Figure 8. Time course of histamine-induced phosphorylation of hKv7.5
channels in cultured HTSMCs. Summarized densitometry results from
immunoprecipitation experiments examining the phosphorylation of hKv7.5
channels in HTSMCs following treatment with vehicle (mKreb’s buffer) or 1 µM
histamine for 0.5, 1, 2, 5, 10 or 30 minutes. hKv7.5 channels were
immunoprecipitated with an anti-FLAG antibody and western blots were probed
with an anti-phosphoserine PKC substrate antibody. Whole cell lysates (25 µg)
were run separately and western blots were probed using an anti-FLAG antibody
to serve as a loading control. Anti-phosphoserine PKC substrate signals were
normalized to anti-FLAG signals from whole cell lysates and vehicle and histamine
treatments were then normalized to untreated control. Each histamine treatment
time point was then normalized to its own vehicle control.
corresponds to threonine 505 (T505) in hKv7.5. In order to determine if
phosphorylation of T505 is necessary for histamine-induced hKv7.5 current
inhibition, a vector was previously created to drive expression of a mutant hKv7.5
in which T505 was replaced by alanine (T505A). Treatment with histamine (1 µM)
and PMA (1 nM) still resulted in significant inhibition of hKv7.5 currents (17.5 ±
6.7% and 52.6 ± 7.6%, respectively, Figure 11A, C) at -20mV. Although it appeared
as if histamine suppressed mutant T505A currents to a lesser extent compared to
WT current suppression, a statistical difference was not reached (Figure 11B).
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There was also no significant difference between WT and T505A channels in the
amount of current inhibition at -20 mV for PMA (Figure 11D). These results indicate
that this particular amino acid residue may be necessary for the regulation of
hKv7.5 currents by histamine, however current results are inconclusive.

Serine Residue 441 is Necessary for Regulation of hKv7.5 Current by
Histamine, but not for Channel Phosphorylation.
MIT NEW Scansite 3 software predicted that hKv7.5 serine residue 441
(S441) to be a potential PKCα phosphorylation site, a residue that also happens
to fall within the recognition sequence for the anti-phosphoserine antibody used in
our previous studies examining hKv7.5 channel phosphorylation following
histamine treatment. In order to determine if S441 phosphorylation is required for
hKv7.5 current inhibition and channel phosphorylation following treatment with
histamine and PMA, a vector was constructed that would drive the expression of
a nonphosphorylatable mutant hKv7.5 in which S441 was replaced by alanine
(S441A). PMA still significantly inhibited hKv7.5-S441A currents (63.0 ± 7.5% at 20 mV, Figure 12C, D), however histamine was unable to suppress hKv7.5-S441A
currents (Figure 12A, B). Despite the lack of histamine-induced hKv7.5-S441A
current

suppression,

a

significant

increase

in

hKv7.5-S441A

channel

phosphorylation was observed upon treatment with either histamine or PMA (1.72
± 0.23 fold and 1.66 ± 0.13 fold, respectively, Figure 13B).
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Figure 9. PKCα is necessary for histamine-induced inhibition of hKv7.5
currents and histamine-induced sustained increases in [Ca2+]cyt in cultured
HTSMCs. (A) I-V curves of steady state currents through hKv7.5 channels
recorded in cultured HTSMCs lacking PKCα before (filled circles) and after
treatment with histamine (1 µM, open circles, n=5). (B) I-V curves of steady state
currents through hKv7.5 channels recorded in cultured HTSMCs expressing
scrambled control shRNA before (filled circles) and after treatment with histamine
(1 µM, open circles, n=4). (C) Averaged time courses of [Ca2+]cyt following
treatment of cultured HTSMCs lacking shPKCα (open circles) or expressing
scrambled control shRNA (closed circles) with histamine (1 µM, n=12). (B)
Summary of 3 experiments (triplicate wells). Data shows average [Ca2+]cyt for the
final 10-15 minutes of treatment (“sustained” [Ca2+]cyt increases) with histamine in
cultured HTSMCs lacking shPKCα (white bar) or expressing scrambled control
shRNA (black bar). *, significant difference from control, p < 0.05, paired t-test. ‡,
significant difference from indicated groups, p < 0.05, one way ANOVA followed
by Holm-Sidak post hoc test, with multiple comparisons among all groups.
Preliminary Mass Spectrometry Results are Inconclusive.
Results thus far implicate S441 as necessary for histamine-induced hKv7.5
current suppression, though immunoprecipitation studies suggest that there are
additional serine residues that are phosphorylated on hKv7.5 channels following
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treatment with histamine. Serine residue 385 (S385) is a putative PKCα
phosphorylation site and also falls within the recognition motif for the antiphosphoserine antibody (-K/R-X-S-FILVY-K/R-) and might contribute to the
remaining signal detected when S441 was mutated to alanine. MIT NEW Scansite
3 also identifies serine residue 772 (S772) as a putative PKC phosphorylation site,
however this particular amino acid does not fall within the recognition motif for the
antibody used.
Our initial mass spectrometry analysis was inconclusive due to low sample
concentration and digestion with trypsin not producing fragments with the amino
acid residues of interest. Our second preliminary mass spectrometry results
indicated that in the EndoQ digested samples for hKv7.5-WT and hKv7.5-S441A
channels, treatment with histamine (1 µM) induced phosphorylation of S385 and
this phosphorylation was not present in untreated samples or samples that had
been pretreated with the PKC inhibitor Ro-31-8220 (1 µM). No S385
phosphorylation

was

observed

in

hKv7.5-T505A

expressing

HTSMCs.

Interestingly, in the same samples digested with EndoK, all samples showed
phosphorylation at S385.
S772 phosphorylation was also observed in nearly all samples from both
EndoQ and EndoK digestions, except for the EndoQ hKv7.5-WT untreated sample
and the hKv7.5-S441A Ro-31-8220 pretreated sample.
A new site not predicted by MIT NEW Scansite 3 software, serine residue
752 (S752), was also phosphorylated in the EndoQ digested hKv7.5-WT histamine
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Figure 10. PKCα is not necessary for histamine-induced increases in hKv7.5
channel phosphorylation in cultured HTSMCs. (A) Representative western blot
of FLAG immunoprecipitates from cultured HTSMCs overexpressing FLAGhKv7.5 channels that expressed scrambled control shRNA or shRNA against
PKCα and were left untreated or treated with histamine (1 µM, 1 minute) probed
with an anti-phosphoserine PKC substrate antibody (top). The same membrane
was probed with an anti-FLAG antibody to serve as a loading control (second from
top). Whole cell lysates (50 µg) were run separately and probed with an anti-PKCα
antibody to confirm PKCα knockdown (second from bottom) and an anti-GAPDH
antibody to serve as a loading control (bottom). (B) Densitometry summarized from
5 experiments. *, significant difference from control, p < 0.05, independent t-test
followed by Mann-Whitney U rank sum test.
treated sample and hKv7.5-S441A histamine and Ro-31-8220 plus histamine
treated sample. No phosphorylation was observed at this site with EndoK digested
samples.
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No phosphorylation at T505 was observed in any samples that contained
an observable fragment, and no fragment containing S441 was analyzed despite
our enzyme selection.
Due to the discrepancies between EndoQ and EndoK samples and the
different phosphorylation patterns that were observed (Table 1), it is important to
repeat these studies before any conclusions can be made.
Retigabine Dose-dependently Relaxes Rat Airways Preconstricted with
Methacholine.
We have demonstrated on multiple occasions that bronchoconstrictor
agonists suppress Kv7 currents in ASMCs (Brueggemann, Kakad et al. 2012,
Haick, Brueggemann et al. 2017). We also observed that the Kv7 channel activator
flupirtine can attenuate histamine-induced bronchoconstriction and that inhibiting
Kv7 channels with XE991 is sufficient to induce robust constriction of human
airways (Brueggemann, Kakad et al. 2012). These observations led us to
hypothesize that Kv7 channel activators represent a novel class of bronchodilators
that may be used in the treatment of asthma.
PCLS were used as an experimental model to further assess the functional
consequences of Kv7 channel manipulation in airway smooth muscle. This in vitro
system allows the user to visualize and monitor the responses of individual airways
to various treatments while allowing for the preservation of cellular processes
within the tissue system and can be used with essentially any mammalian species,
permitting for inter-species comparison and parallel human tissue experimentation
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Figure 11. Threonine 505 may be necessary for histamine-induced
suppression of hKv7.5 currents in cultured HTSMCs. (A) I-V curves of steady
state currents through hKv7.5-T505A channels recorded in cultured HTSMCs
before (filled circles) and after treatment with histamine (1 µM, open circles, n=7).
(B) Summarized data shows average hKv7.5 current at -20 mV under control
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with
histamine (1 µM, dark grey bar, n=6), or following treatment of hKv7.5-T505A
expressing HTSMCs with histamine (1 µM, light great bar, n=7). (C) I-V curves of
steady state currents through hKv7.5-T505A channels recorded in cultured
HTSMCs before (filled circles) and after treatment with PMA (1 nM, open circles,
n=7). (D) Summarized data shows average hKv7.5 current at -20 mV under control
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with
PMA (1 nM, dark grey bar, n=4), or following treatment of hKv7.5-T505A
expressing HTSMCs with PMA (1 nM, light great bar, n=7). *, significantly different
from control, p < 0.05, paired t-test. #, significant difference from indicated groups,
p < 0.05, one way ANOVA on RANKS followed by Dunn’s post hoc analysis, with
multiple comparisons among all groups.
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Figure 12. Serine 441 is necessary for histamine- but not PMA-induced
inhibition of hKv7.5 currents in cultured HTSMCs. (A) I-V curves of steady state
currents through hKv7.5-S441A channels recorded in cultured HTSMCs before
(filled circles) and after treatment with histamine (1 µM, open circles, n=9). (B)
Summarized data shows average hKv7.5 current at -20 mV under control
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with
histamine (1 µM, dark grey bar, n=6), or following treatment of hKv7.5-S441A
expressing HTSMCs with histamine (1 µM, light great bar, n=9). (C) I-V curves of
steady state currents through hKv7.5-S441A channels recorded in cultured
HTSMCs before (filled circles) and after treatment with PMA (1 nM, open circles,
n=6). (D) Summarized data shows average hKv7.5 current at -20 mV under control
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with
PMA (1 nM, dark grey bar, n=4), or following treatment of hKv7.5-T505A
expressing HTSMCs with PMA (1 nM, light great bar, n=6). *, significantly different
from control, p < 0.05, paired t-test. #, significant difference from indicated groups,
p < 0.05, one way ANOVA on RANKS followed by Dunn’s post hoc analysis, with
multiple comparisons among all groups. ‡, significant difference from indicated
groups, p < 0.05, one way ANOVA followed by Holm-Sidak post hoc test, with
multiple comparisons among all groups.

73

Figure 13. Serine 441 is not necessary for histamine- or PMA- induced
phosphorylation of hKv7.5 channels in cultured HTSMCs. (A) Representative
western blot of FLAG immunoprecipitates from cultured HTSMCs overexpressing
FLAG-hKv7.5-WT or FLAG-hKv7.5-S441A channels that were left untreated,
treated with histamine (1 µM, 1 minute), or treated with PMA (1 nM, 30 minutes)
probed with an anti-phosphoserine PKC substrate antibody (top). The same
membrane was probed with an anti-FLAG antibody to serve as a loading control
(bottom). (B) Densitometry summarized from 5 experiments. *, significant
difference from indicated columns, p < 0.05, one-way ANOVA followed by HolmSidak post hoc test, with multiple comparisons versus control group.
(Liberati, Randle et al. 2010, Sanderson 2011). Retigabine dose-dependently
relaxed rat airways preconstricted with 230 nM methacholine, the approximate
EC50 for methacholine in rat airways (Brueggemann, Haick et al. 2014) (EC50=3.6
± 0.3 µM; maximum relaxation 61  9%, Figure 14B). Retigabine-induced
relaxation was rapid and sustained through the entire treatment period (Figure
14A).
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Table 1. Preliminary Mass Spectrometry Results. Phosphorylation sites of
interest on hKv7.5 channels. HTSMCs expressing FLAG-hKv7.5-WT, FLAGhKv7.5-S441A, or FLAG-hKv7.5-T505A channels were left untreated, treated with
1 µM histamine for 1 minute, or pretreated with 1 µM Ro-30-8220 for 1 hour prior
to treatment with 1 µM histamine prior to immunoprecipitation with an anti-FLAG
antibody. Each sample was digested with EndoK (“K”) and EndoQ (“Q) and
subjected to mass spectrometry analysis. K or Q identifies residues where
phosphorylation was detected for each enzymatic digest.
Formoterol Dose-dependently Relaxes Rat Airways Preconstricted with
Methacholine.
Formoterol is a commonly prescribed LABA that is typically used for
“maintenance” therapy, but also produces rapid and effective bronchodilation
during acute asthma attacks (Rodrigo, Neffen et al. 2010, Ricciardolo, Blasi et al.
2015). Similar to retigabine, formoterol dose-dependently relaxed rat airways
preconstricted with 230 nM methacholine (EC50=2.4 ± 0.3 nM; maximum relaxation
72  5%, Figure 15B), however there was a substantial time-dependent decline in
relaxation by the end of the treatment period (Figure 15A).
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Figure 14. Retigabine dose-dependently relaxes rat airways preconstricted
with methacholine. (B) Representative time course depicting the changes in area
of a single rat airway (pictured in (A)) treated with methacholine (230 nM, 30
minutes), followed by retigabine (10 µM) in the continued presence of
methacholine (30 minutes), and then washed. (C) Averaged dose-response curve
of retigabine-induced relaxation of rat airways preconstricted with methacholine
(230 nM) fitted to the Hill equation (n=6).
Retigabine Enhances Formoterol-induced Relaxation of Rat Airways
Preconstricted with Methacholine.
Airways were constricted with 230 nM methacholine and then a submaximal
concentration of retigabine (10 µM) was included with the different increasing
concentrations of formoterol (Figure 16A). The addition of retigabine increased
both the maximal and the sustained airway relaxation compared to formoterol
alone (Figure 16B) and also significantly decreased the time-dependent decline in
airway relaxation initially observed with formoterol treatment alone (Figure 16C).
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The time-dependent decline in airway relaxation, or “desensitization”, to
formoterol treatment was of particular interest and warranted further investigation.
There is considerable evidence that regular use of long-acting β2-agonists, such
as salmeterol or formoterol, for the treatment of asthma, results in the development
of tolerance and reduced efficacy. When formoterol (10 nM) was used repetitively
as a bronchodilator on a single airway, a time-dependent decline in relaxation was
observed during each consecutive application and there was also an overall
decrease in the final extent of relaxation achieved following successive formoterol
applications (Figure 17A). The initial maximum relaxation peaked at 68 ± 10% and
tapered significantly to a final relaxation of 46 ± 14% after 30 minutes. The second
application of formoterol reached a maximum relaxation of only 48 ± 8% and
declined to a final relaxation of 32 ± 6% after 30 minutes (Figure 17C). Adding
retigabine (10 µM) to the second application of formoterol resulted in significantly
greater relaxation (72 ± 8%, maximum and final relaxation, Figure 17B, D) and
there was no time-dependent decline in relaxation after 30 minutes.

Retigabine Appears to Enhance Formoterol-induced Relaxation of Human
Airways Preconstricted with Histamine.
Formoterol (10 pM) was applied repetitively to human airways constricted
with 50 nM histamine. Although a time-dependent decline in formoterol-induced
relaxation was not observed, the second consecutive application of formoterol
results on average in a smaller amount of relaxation (29 ± 10.5% and 8 ± 11.9%
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Figure 15. Formoterol dose-dependently relaxes rat airways preconstricted
with methacholine. (B) Representative time course depicting the changes in area
of a single rat airway (pictured in (A)) treated with methacholine (230 nM, 30
minutes), followed by formoterol (10 nM) in the continued presence of
methacholine (30 minutes), and then washed. (C) Averaged dose-response curve
of maximum formoterol-induced relaxation of rat airways preconstricted with
methacholine (230 nM) fitted to the Hill equation (n=6).
relaxation, respectively, Figure 18A, C). When retigabine (10 µM) is included with
the second application of formoterol, airways relax to a greater extent than the
initial formoterol treatment (28 ± 6.7% and 58 ± 16.9%, respectively, Figure 18B,
C). While retigabine’s ability to enhance formoterol-induced airway relaxation is
approaching significance, additional studies are required before any conclusions
can be drawn.
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Retigabine Relaxes OVA-sensitized Guinea Pig Airways Preconstricted with
Methacholine.
Results thus far indicate that retigabine is an effective bronchodilator in
normal rat and human airways, however it is necessary to determine if retigabine
retains its bronchodilatory effects in asthmatic airways. Seeing as the availability
of human tissue, particularly asthmatic tissue, can be limited, it is beneficial to have
an animal model system that is comparable to human. The guinea pig model of
allergic asthma is commonly used to observe and test airway hyperresponsiveness
(Meurs, Gosens et al. 2008, McGovern and Mazzone 2014). PCLS prepared from
guinea pigs are considered to be a more appropriate model than rat or mouse
(Ressmeyer, Larsson et al. 2006) and the late asthmatic responses and immediate
hypersensitivity to irritants following sensitization in guinea pigs are comparable to
the human allergic response (Meurs, Gosens et al. 2008).
Our laboratory has adopted a guinea pig OVA-sensitization protocol that
consistently induces asthma-like symptoms upon exposure to nebulized OVA.
Briefly, male Hartley guinea pigs are given 3 intraperitoneal injections of OVA or
saline (control) on days 1, 3 and 5. Following a 2 week sensitization period, the
animals are exposed on 3 successive days to a fine mist of OVA for 30 minutes
while being monitored for symptoms such as chewing, labored breathing,
coughing, and gasping. Tissues are collected post-euthanasia for PCLS. OVA
produces robust constriction of airways in PCLS from sensitized but not control
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Figure 16. Retigabine enhances formoterol-induced relaxation of rat airways
preconstricted with methacholine. (A) Representative time course depicting the
changes in area of a single rat airway treated with methacholine (230 nM, 30
minutes), followed by formoterol (10 nM) plus retigabine (10 µM) in the continued
presence of methacholine (30 minutes), and then washed. (B) Summarized bar
graph depicting the maximum (solid bars) and final (checkered bars) amount of
formoterol (blue bars) versus formoterol plus retigabine (10 µM, green bars)
induced relaxation of rat airways preconstricted with methacholine (230 nM) (n=6).
(C) Summarized bar graph depicting formoterol (blue striped bars) versus
formoterol plus retigabine (10 µM, green striped bars) maximum minus final
relaxation, or the total time-dependent decline in relaxation during the 30 minute
treatment period. *, significant difference between indicated group, p < 0.05,
student’s t-test.
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Figure 17. Retigabine attenuates the time-dependent decline in formoterolinduced relaxation of rat airways preconstricted with methacholine observed
upon repetitive administration. (A) Representative time course depicting the
changes in area of a single rat airway treated with methacholine (230 nM, 30
minutes), followed by formoterol (10 nM) in the continued presence of
methacholine (30 minutes), with a 45 minute washout period between
methacholine-induced constrictions. (B) Representative time course depicting the
changes in area of a single rat airway treated with methacholine (230 nM, 30
minutes), followed by formoterol (10 nM) or formoterol (10 nM) plus retigabine (10
µM) in the continued presence of methacholine (30 minutes), with a 45 minute
washout period between methacholine-induced constrictions. (C) Summarized bar
graph depicting the average maximum and final relaxation of airways for each
application of formoterol, from experiments depicted in A (n=6). (D) Summarized
bar graph depicting the average maximum and final relaxation of airways for
formoterol and formoterol plus retigabine, from experiments depicted in B (n=6). *,
significant difference from max1, p < 0.05, one way repeated measures ANOVA.
#, significant difference from max1, max2, and final2, p < 0.05 one way repeated
measures ANOVA.
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Figure 18. Retigabine appears to attenuate the time-dependent decline in
formoterol-induced relaxation of human airways preconstricted with
histamine observed upon repetitive administration. (A) Representative time
course depicting the changes in area of a single human airway treated with
histamine (50 nM, 30 minutes), followed by formoterol (10 pM) in the continued
presence of histamine (30 minutes), with a 45 minute washout period between
histamine-induced constrictions. (B) Representative time course depicting the
changes in area of a single human airway treated with histamine (50 nM, 30
minutes), followed by formoterol (10 pM) or formoterol (10 pM) plus retigabine (10
µM) in the continued presence of histamine (30 minutes), with a 45 minute washout
period between histamine-induced constrictions. (C) Summarized bar graph
depicting the average repetitive formoterol induced relaxation or formoterol then
formoterol plus retigabine induced relaxation of human airways (n=5).
animals and PCLS from OVA-sensitized animals show increased sensitivity to the
bronchoconstrictor agonists methacholine and histamine (Kakad 2012).
100 nM methacholine (the approximate EC50 in control guinea pig airways,
(Kakad 2012)) was used to constrict control guinea pig airways prior to treatment
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with 30 µM retigabine (the concentration used in our asthmatic human PCLS
experiment) in the presence of methacholine. Treatment with retigabine produced
significant airway relaxation (32 ± 8.3%, Figure 19A, C). Retigabine vehicle did not
significantly relax airways (Figure 19B, D). Similar results were observed for OVAsensitized guinea pig airways (29 ± 5.8% relaxation, Figure 20).

Retigabine Attenuates OVA-induced Allergic Asthma Symptoms in OVASensitized Guinea Pigs.
A set of pilot studies were completed to determine if retigabine was capable
of attenuating the allergic asthma symptoms displayed by OVA-sensitized guinea
pigs during the nebulized OVA challenges. When the unanaesthetized guinea pig
was exposed to nebulized OVA alone, symptoms such as coughing and rapid,
labored breathing, occurred within minutes. The animal was rescued from the
chamber when the symptoms become too severe, approximately 15 minutes into
the 30 minute challenge. Once removed from the chamber, the guinea pig was
weak and lethargic, requiring a monitored recovery period. When retigabine (1
mM) was included with the nebulized OVA, the same guinea pig did not develop
symptoms until approximately 18-22 minutes into the challenge and the symptoms
were not nearly as severe as those observed with nebulized OVA alone. The
animal withstood the entire 30 minute challenge and was alert once removed from
the chamber. A parallel study was completed with control guinea pigs that showed
no observable effects of either nebulized OVA or nebulized OVA plus retigabine.
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Figure 19. Retigabine relaxes control guinea pig airways preconstricted with
methacholine. (A) Representative time course depicting the changes in area of a
single guinea pig airway treated with methacholine (100 nM, 30 minutes), then
retigabine (30 µM) in the continued presence of methacholine (45 minutes),
followed by removal of retigabine (30 minutes) and washout. (B) Representative
time course depicting the changes in area of a single guinea pig airway treated
with methacholine (100 nM, 30 minutes), then retigabine vehicle in the continued
presence of methacholine (45 minutes), followed by removal of retigabine vehicle
(30 minutes) and washout. (C) Summarized bar graph depicting average airway
area relative to control (black bar, average of 5 minutes before methacholine
treatment) upon treatment with methacholine (100 nM, grey bar), methacholine
and retigabine (30 µM, yellow bar), and removal of retigabine (grey bar) from
experiments depicted in A. (D) Summarized bar graph depicting average airway
area relative to control (black bar, average of 5 minutes before methacholine
treatment) upon treatment with methacholine (100 nM, grey bar), methacholine
and retigabine vehicle (grey bar), and removal of retigabine vehicle (grey bar) from
experiments depicted in B. *, significant difference, p < 0.05, one way ANOVA
followed by Holm-Sidak post hoc test, with multiple comparisons.
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Figure 20. Retigabine relaxes OVA-sensitized guinea pig airways
preconstricted with methacholine. (A) Representative time course depicting the
changes in area of a single guinea pig airway treated with methacholine (100 nM,
30 minutes), then retigabine (30 µM) in the continued presence of methacholine
(45 minutes), followed by removal of retigabine (30 minutes) and washout. (B)
Representative time course depicting the changes in area of a single guinea pig
airway treated with methacholine (100 nM, 30 minutes), then retigabine vehicle in
the continued presence of methacholine (45 minutes), followed by removal of
retigabine vehicle (30 minutes) and washout. (C) Summarized bar graph depicting
average airway area relative to control (black bar, average of 5 minutes before
methacholine treatment) upon treatment with methacholine (100 nM, grey bar),
methacholine and retigabine (30 µM, yellow bar), and removal of retigabine (grey
bar) from experiments depicted in A. (D) Summarized bar graph depicting average
airway area relative to control (black bar, average of 5 minutes before
methacholine treatment) upon treatment with methacholine (100 nM, grey bar),
methacholine and retigabine vehicle (grey bar), and removal of retigabine vehicle
(grey bar) from experiments depicted in B. *, significant difference, p < 0.05, one
way ANOVA followed by Holm-Sidak post hoc test, with multiple comparisons.
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Guinea Pig flexiVent Optimization Experiments and Troubleshooting.
The results from our PCLS experiments and the nebulized retigabine pilot
studies suggest that activating Kv7 channels represents a novel approach to
asthma therapy. Our next goal was to quantitatively examine the bronchodilatory
effects of retigabine using an in vivo approach. Naïve guinea pigs were
mechanically ventilated while under anesthesia and a variety of respiratory
parameters, such as respiratory resistance, Newtonian resistance, tissue
dampening, and tissue elastance, were measured using a small animal ventilator
called a flexiVent controlled by flexiWare software. Once a stable baseline
respiratory resistance value was obtained, the animals were given i.v. or nebulized
histamine or methacholine at approximately 5 minute intervals. Following each
administration of bronchoconstrictor, respiratory parameters were recorded using
the series of “snapshot” and “quick prime-6” maneuvers during the 5 minute
interval.
A variety of experimental approaches were attempted during this
optimization study on naïve guinea pigs with the hopes to establish a protocol that
could be used to determine if nebulized Kv7 channel activators were capable of
attenuating

the

increase

in

respiratory

resistance

observed

upon

bronchoconstrictor agonist treatment. Each experiment typically began with
establishing a dose-response for the i.v. or nebulized bronchoconstrictor. In some
instances we would repeat the dose-response to examine the reproducibility in the
same animal. The dose-responses were reproducible, however we occasionally
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Figure 21. Repetitive intravenous histamine with increasing concentrations
of nebulized retigabine. Representative experiment depicting respiratory
resistance measured in an anesthetized and mechanically ventilated following the
indicated treatments. Vehicle (water) or increasing concentrations of retigabine (110 mM) were nebulized prior to each intravenous injection of histamine (2 µg/kg).
Respiratory resistance was determined using the flexiWare “snapshot” maneuver
following histamine injection.
observed increased sensitivity to the bronchoconstrictor agonist following multiple
applications. After establishing a dose-response, we selected an approximate
EC50 dose and tested for reproducibility upon multiple administrations. The multiple
i.v. approximate EC50 doses tended to be more reproducible than multiple
nebulized approximate EC50 doses. The addition of nebulized Kv7 channel
activator (1, 5, or 10 mM retigabine, 10 mM flupirtine, 1 or 10 mM ML213) with
either i.v. or nebulized bronchoconstrictor did not have an appreciable effect on
the increases in respiratory resistance. There was one instance where nebulized
1, 5, and 10 mM retigabine attenuated the increase in respiratory resistance
observed during the first of three i.v. histamine approximate EC50 doses (Figure
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21), however the second and third doses resulted in an increase in respiratory
resistance comparable to histamine alone despite nebulizing retigabine prior to
each i.v. administration. We were able to establish a positive control, 28 µM
nebulized formoterol, which consistently attenuated the increased respiratory
resistance observed following bronchoconstrictor agonist treatment.
We decided to try a different approach for the remainder of our approved
optimization experiments. First, we would limit the nebulized bronchoconstrictor
dose-response so that respiratory resistance only increased to 2-3 times over the
initial baseline. This way we were not working with too high of a bronchoconstrictor
concentration to observe any protective effects offered by the Kv7 channel
activators. We also decided to add a nebulized Kv7 channel activator pretreatment
period that attempted to mimic the extended exposure to retigabine during our pilot
studies (see Retigabine attenuates OVA-induced allergic asthma symptoms in
guinea pigs). Following the establishment of a dose-response, retigabine would be
nebulized approximately every minute for an extended period of time (initially 30
minutes, but we decreased the time to 18 minutes to avoid potential
fluid/obstruction buildup associated with prolonged nebulization), and this
pretreatment period would also include deep breaths to ensure that retigabine was
reaching the airways. A second dose-response would then be completed to
determine if the Kv7 channel activator attenuated the observed increases in
respiratory resistance. When the vehicle for retigabine, water, was nebulized
during the pretreatment period, there was no effect observed on the respiratory
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Figure 22. Repetitive nebulized methacholine dose response with nebulized
retigabine pretreatment. Representative experiment depicting respiratory
resistance measured in an anesthetized and mechanically ventilated following the
indicated treatments. Vehicle (water) or retigabine (1 mM) was nebulized
approximately every minute for 18 minutes in between treatment with increasing
doses of nebulized methacholine (0.0-0.3 mg/ml). Respiratory resistance was
determined using the flexiWare “snapshot” maneuver.
resistance dose-response. Unfortunately, we also did not observe any protective
effects of retigabine following pretreatment (Figure 22). There was a single
instance where pretreating with 10 mM retigabine and including 10 mM retigabine
in the second methacholine dose-response appeared to attenuate the increase in
respiratory resistance, however we were unable to repeat this result by the
conclusion of our allotted optimization experiments. An interesting and consistent
result was the lowering of respiratory resistance compared to the initial baseline
respiratory resistance following the retigabine pretreatment period (Figure 23).
Although these optimization experiments indicate that retigabine is not offering
protection against bronchoconstrictor agonist-induced increases in respiratory
resistance in these instances, there is some potentially beneficial effect of
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Figure 23. Nebulized retigabine lowers baseline respiratory resistance.
Depiction of the average respiratory resistance values measured using the
flexiWare “snapshot” maneuver during the vehicle (water) or retigabine (10 mM)
“pretreatment” nebulizing period. Values were normalized to the initial baseline
resistance for each animal. *, significant difference, p < 0.05, student’s t-test.
nebulized retigabine. Additional studies to establish a protocol examining the
therapeutic potential of Kv7 channel activators in vivo would need to be completed
before any conclusions can be drawn.

CHAPTER SIX
DISCUSSION
Our previous examination of ASMCs revealed the presence of Kv7 K+
currents that were inhibited upon treatment of the cells with bronchoconstrictor
agonists. Inhibition of Kv7 channels with the specific blocker XE991 was sufficient
to induce constriction of human airways, and this inhibition was reversed upon
blocking L-type VSCCs with verapamil. Lastly, activation of Kv7 channels
attenuated histamine-induced constriction of human airways (Brueggemann,
Kakad et al. 2012). These results highlighted the importance of Kv7 channels in
the regulation of airway smooth muscle tone, however additional studies would be
necessary to clarify the specifics of this role and to examine the therapeutic
potential of targeting Kv7 channels for bronchodilator therapy.
The work presented in this dissertation aimed to (1) elucidate the
mechanism by which the bronchoconstrictor agonist histamine regulates Kv7
channels in airway smooth muscle and (2) determine the efficacy of Kv7 channel
activators in attenuating agonist-induced bronchoconstriction and explore their
therapeutic potential for the treatment of asthma. Experiments completed in
parallel with this project outlined in this dissertation revealed that the
bronchoconstrictor agonist histamine enhanced phosphorylation of endogenous
Kv7.5 channels in freshly isolated human trachealis smooth muscle and inhibited
endogenous Kv7 currents in cultured HTSMCs (Haick, Brueggemann et al. 2017).
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Using low-passage cultured HTSMCs as an expression system, we
determined that activation of PKC, both directly with PMA or indirectly with
histamine, increased phosphorylation of hKv7.5 channels (Figure 7) and inhibited
hKv7.5 currents (Figure 4). The effects of histamine on the phosphorylation status
of the channels and on the inhibition of hKv7.5 currents occurred in a PKCdependent manner, evidenced by an attenuation of hKv7.5 phosphorylation and
current inhibition when PKC was inhibited prior to histamine treatment (Figure 7,
5). The regulation of hKv7.5 currents by histamine appears to be dependent on
PKCα specifically (Figure 9), as well as a serine residue located at position 441
(Figure 12). Surprisingly the loss of PKCα or the mutation of serine 441 to alanine
did not attenuate histamine-induced phosphorylation of hKv7.5 channels (Figure
10, 13) even though it prevented histamine-induced regulation of hKv7.5 currents.
We also provide evidence that illustrated the ability of Kv7 channel activation to
relax rat, guinea pig, and human airways that had been constricted with
bronchoconstrictor agonists and highlight a promising and novel therapeutic
approach to treat asthma that should continue to be investigated.
The suppression of Kv7 currents following Gq-coupled receptor activation
has been extensively examined in neurons (Marrion 1997, Delmas and Brown
2005) and more recently in vascular smooth muscle (Mackie, Brueggemann et al.
2008, Mani, O'Dowd et al. 2013, Brueggemann, Mackie et al. 2014). As mentioned
in chapter 2, PKC is one common effector of Gq-coupled agonist-induced inhibition
of Kv7 currents, however the PKC-dependent nature of agonist-induced
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suppression of Kv7 currents in airway smooth muscle has not been investigated
until now. PKC is also an established regulator of ASMC contraction and airway
constriction (Webb, Hirst et al. 2000). Evidence suggests that phosphorylation of
a variety of substrates, particularly those involved in the regulation of a cell’s
contractile machinery (Pohl, Winder et al. 1997, Webb, Hirst et al. 2000, Sakai,
Chiba et al. 2005), are responsible for the contractile effects of PKC activation.
However, there is also a component of PKC-induced Ca2+ signaling in ASMCs and
airway smooth muscle constriction that is dependent on extracellular Ca2+ and Ltype VSCCs (Park and Rasmussen 1985, Knox, Baldwin et al. 1993, Rossetti,
Savineau et al. 1995, Yang and Black 1996, Mukherjee, Trice et al. 2013) that
cannot be explained by phosphorylation of the previously identified targets. Results
presented in this dissertation have also highlighted the importance of L-type
VSCCs in the sustained [Ca2+]cyt elevation observed following treatment of
HTSMCs with histamine (Figure 3). Evidence suggests that inhibition of Kv7
channels in vascular smooth muscle results in membrane depolarization that
promotes the activation of L-type VSCCs (Mackie, Brueggemann et al. 2008). We
have established that histamine inhibits Kv7 channels in ASMCs (Brueggemann,
Kakad et al. 2012) and upon completion of this project have determined that this
occurs in a PKC-dependent manner. We have also demonstrated that inhibition of
Kv7 currents is sufficient to depolarize ASMC membranes (Haick, Brueggemann
et al. 2017). Therefore, it is reasonable to predict that the L-type VSCC-dependent
effects of PKC activation (increases in [Ca2+]cyt and contraction of airway smooth
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muscle may be occurring, at least in part, as a result of inhibition of Kv7 channels
(Figure 24).
Multiple PKC isoforms have been found to be expressed in ASMCs (Webb,
Lindsay et al. 1997, Sakai, Yamamoto et al. 2009), however the specific isoform(s)
behind the PKC-dependent effects observed in airway smooth muscle have yet to
be identified (Webb, Hirst et al. 2000). PKCα was a particularly promising
candidate for the histamine-induced phosphorylation of hKv7.5 channels and
inhibition of their currents. In vascular smooth muscle, histamine treatment
resulted in redistribution of PKC activity from the cytosol to the plasma membrane
(Haller, Smallwood et al. 1990) and PKCα specifically has been implicated in the
phosphorylation of vascular smooth muscle contractile proteins and phorbol esterinduced constriction of rabbit femoral arteries (Eto, Kitazawa et al. 2001).
Histamine treatment has also been demonstrated to induce PKCα translocation
from cytosol to membranes in a HeLa cell expression system (Rimessi, Rizzuto et
al. 2007) and in CHO-H1 cells (Megson, Walker et al. 2001). Indeed, PKCα was
found to be necessary for histamine-induced inhibition of hKv7.5 currents in
cultured HTSMCs (Figure 9). However, when we measured total phosphorylation
with an anti-phosphoserine PKC substrate antibody, we still observed a significant
increase in histamine-induced phosphorylation of hKv7.5 channels (Figure 10).
Although this result was unexpected, all PKC isoforms except γ have been
detected in cultured human ASMCs (Carlin, Yang et al. 1999) and it is possible
that treatment of HTMSCs with histamine results in the activation of additional PKC
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Figure 24. Proposed role of Kv7 channels and L-type VSCCs following Gqcoupled receptor signaling in ASMCs. ASMC contraction has a voltagedependent component of Ca2+ influx necessary for sustained contraction
evidenced to occur through L-type voltage sensitive Ca2+ channels (VSCC). We
hypothesize that the stimulus for the membrane depolarization necessary for Ltype VSCC activation occurs via PKC-dependent suppression of Kv7 currents,
highlighted in grey. We hypothesize that the stimulus for the membrane
depolarization necessary for L-type VSCC activation occurs via PKC-dependent
suppression of Kv7 currents, highlighted in grey.
isoforms that phosphorylate hKv7.5 channels. It is important to note that PKCα
specifically is necessary for histamine-induced suppression of hKv7.5 currents in
HTSMCs and that any additional phosphorylation by other PKC isoforms is likely
unrelated to histamine-induced effects on hKv7.5 currents.
Repeating the immunoprecipitation experiments with other PKC isoforms
knocked down, either individually or in combination with PKCα, is one potential
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area of exploration that may elucidate additional PKC isoforms that phosphorylate
hKv7.5 channels following histamine treatment. Examining the residues on hKv7.5
that are phosphorylated in response histamine treatment of HTSMCs under normal
conditions and comparing them to the same samples that lack PKCα, or other PKC
isoforms, using mass spectrometry would also give important insight into not only
which PKC isoforms phosphorylate hKv7.5 channels but also which amino acid
residues are important in histamine-induced hKv7.5 regulation.
The work completed in this dissertation indicates that threonine residue 505,
a residue that corresponds with rat Kv7.2 serine 534 that has been identified as a
PKC phosphorylation site on that channel (Hoshi, Zhang et al. 2003), may also be
required for histamine-induced suppression of hKv7.5 currents in ASMCs (Figure
11). Results suggest that histamine was still able to significantly suppress the
mutant hKv7.5 currents. It appears that histamine suppresses hKv7.5 T505A
channels to a lesser extent, however a significant difference was not observed.
Our laboratory has observed decreased sensitivity of hKv7.5 T505A mutant
channels to AVP-induced current suppression in A7r5 cells (LI Brueggemann,
unpublished), therefore it is possible that mutation of this residue results in the
decreased sensitivity of hKv7.5 currents to histamine as well.
Although the effect of T505 mutation was inconclusive, our results indicate
that hKv7.5 residue serine 441 is absolutely necessary for histamine-induced
suppression of hKv7.5 currents (Figure 12). This residue was selected due to its
position in the recognition motif for the anti-phosphoserine antibody used in our
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immunoprecipitation studies (-K/R-X-S-FILVY-K/R-). Mutation of S441 to nonphosphorylatable alanine abolished histamine’s ability to inhibit hKv7.5 currents
(Figure 12), but interestingly did not attenuate histamine-induced phosphorylation
of hKv7.5 (Figure 13). This indicates that there are likely other hKv7.5 amino acid
residues that are phosphorylated in response to treatment with histamine, however
they do not appear to be necessary for histamine-induced regulation of hKv7.5
currents.
Serine 385 also matches the consensus motif recognized by the antibody
and may contribute to the remaining signal detected in our immunoprecipitation
studies when S441 was mutated to alanine. EndoQ digested mass spectrometry
studies suggest that this may indeed be the case (Table 1), however the
experiment must be repeated before any conclusions can be made considering
the observation of S385 phosphorylation in all EndoK digested samples. One
potentially interesting observation was the lack of S385 phosphorylation following
histamine treatment of the EndoQ digested hKv7.5-T505A expressing HTSMCs. It
would also be of interest to examine the levels of S441 phosphorylation in the
hKv7.5-T505A mutant samples. Seeing as the T505A mutant channels may be
less sensitive to regulation by histamine, perhaps sequential phosphorylation of
amino acid residues (T505 then S385 and/or S441) is necessary for normal
regulation of the channel by histamine.
Although the electrophysiology studies completed in this dissertation
suggest that phosphorylation of S441 is necessary for histamine-induced Kv7.5
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current suppression, confirmation of S441 phosphorylation, as well as
identification of other amino acids that are phosphorylated following treatment with
histamine, should be assessed by completing additional mass spectrometry
studies. It is essential to find a protocol that will allow for segments containing S441
to be analyzed, considering that the EndoQ and EndoK sample digestions proved
unsuccessful in that regard. Re-examining S385 is also of particular interest due
to the preliminary mass spectrometry results and the fact that this residue is
recognized by the antibody used in all of our previous studies.
The framework for elucidating the mechanism of histamine-induced
regulation of hKv7.5 channels has been completed in the work presented in this
dissertation. Confirming what we have learned thus far, as well as answering the
questions that remain with the proposed experiments, will aid in establishing a
clearer pathway of bronchoconstrictor agonist-induced regulation of hKv7.5
channels in HTSMCs.
The second portion of this project aimed to examine the ability of Kv7
channel activators to attenuate agonist-induced bronchoconstriction and begin to
determine their therapeutic potential for the treatment of asthma. First we used
PCLS to examine the bronchodilatory capabilities of the clinically available Kv7
channel activator retigabine and compared it to that of the LABA formoterol.
Retigabine dose-dependently relaxed rat airways that were preconstricted with
methacholine (Figure 14). Prolonged use of β2-agonists has been reported to result
in tachyphylaxis, or tolerance; it is believed to result from β2-adrenergic receptor
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desensitization and leads to decreased sensitivity to bronchodilator therapy and
ultimately poor symptom management (Cazzola, Page et al. 2013). This
phenomenon was exhibited in our rat PCLS model: while formoterol was capable
of relaxing preconstricted rat airways, there was a time-dependent decline in
relaxation observed during the 30 minute treatment period (Figure 15) that had not
been observed with retigabine treatment alone. Enhanced relaxation was
observed for some concentrations of formoterol upon inclusion of a submaximal
dose of retigabine and the time-dependent decline observed over the 30 minute
treatment period was significantly reduced when compared to formoterol treatment
alone (Figure 16). We decided to take advantage of the time-dependent
desensitization observed upon formoterol treatment in our rat PCLS model and
found that consecutive applications of formoterol to airways that had been
reproducibly constricted with methacholine resulted in a similar occurrence (Figure
17). When a submaximal concentration of retigabine was added to the second
application of formoterol, there was no time-dependent decline in airway relaxation
at the end of the 30 minute treatment period and the final airway relaxation was
significantly greater than that achieved during the first application of formoterol
alone (Figure 17).
The effects observed combining retigabine and formoterol were not
additive. One mechanism of airway relaxation following Gs-coupled receptor
stimulation with LABAs occurs through the activation of BK channels and
subsequent hyperpolarization of ASMC membranes. Activation of Kv7 channels is
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also expected to induce airway relaxation via membrane hyperpolarization. These
two mechanisms may be somewhat redundant under normal conditions, however
Kv7-channel induced membrane depolarization appears to substitute for the loss
of BK-channel induced membrane hyperpolarization following the Gs-coupled
receptor desensitization that occurs following prolonged β2-agonist treatment.
Combination bronchodilator therapies, specifically a LABA combined with a
muscarinic antagonist, have been associated with several benefits (Cazzola, Page
et al. 2013). The results observed in rat and human airways highlight the potential
of Kv7 channel activators, retigabine in particular, to act as a bronchodilator, either
alone or in combination with currently available bronchodilator therapy.
Aside from a single experiment examining the ability of retigabine to
enhance formoterol induced bronchodilation in a manner similar to figure 17 using
PCLS prepared from asthmatic tissue, little has been done to confirm the ability of
Kv7 channel activators to relax airways in as asthmatic state. The availability of
human tissue, especially asthmatic human tissue, is quite limited, therefore it was
important for us to adopt an animal model of allergic asthma. The guinea pig model
of allergic asthma is commonly used to observe and test AHR (Meurs, Gosens et
al. 2008, McGovern and Mazzone 2014). PCLS prepared from guinea pigs are
often considered to be a more appropriate model than rat or mouse (Ressmeyer,
Larsson et al. 2006) and the late asthmatic responses and immediate
hypersensitivity to irritants following sensitization in guinea pigs are comparable to
the human allergic response (Meurs, Gosens et al. 2008).
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The OVA-sensitization guinea pig model we adopted yields PCLS from
OVA-sensitized animals that are more sensitive to the bronchoconstrictor agonists
methacholine and histamine, a classic manifestation of AHR, when compared to
PCLS from control animals (Kakad 2012). It is also interesting to note a
downregulation of Kv7 channel expression that was observed when comparing
sensitized to control guinea pig ASMCs (Kakad 2012). Our initial studies using
guinea pig PCLS were largely successful, however recent attempts to examine the
ability of retigabine to relax airways preconstricted with methacholine presented
more of a technical challenge. Despite the presence of the β2-agonist isoproterenol
in many of the isolation solutions and media, airways often constricted following
PCLS preparation, likely due to the substance P-induced postmortem constriction
that occurs in guinea pig airways (Lai, Lamm et al. 1984, Lai and Cornett 1987).
We also observed considerable variation in the sensitivity of the guinea pig airways
to methacholine. Some airways would not respond while other airways from the
same preparation, or even the same lobe, would completely occlude. Our previous
experiences with PCLS preparations from rat or human tissues were more
consistent and predictable.
Despite these difficulties, a set of experiments comparing the ability of
retigabine to relax guinea pig airways preconstricted with methacholine in control
and OVA-sensitized tissues were completed (Figure 19, 20). Retigabine relaxed
airways to a similar extent (approximately 30%) in both control and sensitized
tissues. This occurred despite the decrease in Kv7 channel expression in
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sensitized tissues (Kakad 2012), implying that targeting the remaining Kv7
channels with retigabine is sufficient to induce airway relaxation. These results,
combined with the study completed in asthmatic human tissue, are indicative of
the ability of retigabine to relax diseased airways and provide additional support
for Kv7 channels to act as therapeutic targets for the treatment of asthma.
Our in vitro results were promising and warranted further investigation. The
guinea pig OVA-model allows us to test the effectiveness of retigabine as a
bronchodilator in vivo as well. An initial pilot study examined the ability of retigabine
to attenuate the asthma-like symptoms observed during nebulized OVA
challenges with OVA-sensitized guinea pigs. The results provided the first
evidence of the in vivo potential of Kv7 channel activators as novel asthma
therapeutics. The presence of retigabine along with the nebulized OVA offered
such substantial protection that only minor symptoms were observed towards the
end of the 30 minute challenge period instead of the standard 7-8 minutes into the
challenge observed with nebulized OVA alone. The OVA-sensitized guinea pig
also lasted the entire 30 minutes of the challenge without having to be rescued
from the chamber, as opposed to approximately 15 minutes typically observed with
nebulized OVA alone. Upon removal from the chamber, the guinea pig was alert
and active and did not require any monitored recovery time.
These results were encouraging, but qualitative in nature. In order to
quantitatively measure the bronchodilatory capabilities of retigabine in vivo, we
sought to develop a protocol using a flexiVent computer-controlled small animal
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ventilator. Our initial plan was to test if nebulized retigabine offered protection
against

the

increases

bronchoconstrictor

agonist

in

respiratory

treatment. In

resistance
our

first

observed
flexiVent

following

optimization

experiments, retigabine was nebulized directly prior to either nebulized or i.v.
administration of bronchoconstrictor. There was only one instance where
nebulized retigabine appeared to offer protection from i.v. histamine-induced
increases in respiratory resistance (Figure 21), however this result was not
reproducible, even in the same experiment. Similarly, retigabine did not offer
protection from nebulized bronchoconstrictor challenge when nebulized prior to or
in combination with the bronchoconstrictor.
After our initial inconclusive results observed during the first portion of our
optimization studies, we decided to adjust our protocol. First, we limited our
bronchoconstrictor challenges to concentrations that induced an increase in
respiratory resistance of only 2-3 times the initial baseline value. This would
prevent us from using an agonist concentration that is too high and prevent
unnecessary stress on the animal and its respiratory system. We also wanted to
determine if keeping the bronchoconstrictor doses low would offer an improved
chance of observing an attenuation of respiratory resistance increases following
retigabine treatment. We also attempted to mimic the pilot studies as closely as
possible. Our pilot study delivered a continuous mist of 1 mM retigabine in the
presence of OVA to a consciously breathing animal. Unfortunately, the flexiVent is
limited in that a continuous mist of retigabine is not possible. However, a
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“pretreatment” regimen was developed in an attempt to deliver more retigabine to
the airways. This “pretreatment” consisted of nebulizing vehicle (water) or
retigabine approximately every minute for 18 minutes in between the nebulized
bronchoconstrictor dose-response protocols. We also included deep breathes
following each nebulization of retigabine in order to ensure that it was being
delivered to the airways.
Despite the changes made to the protocol, we did not observe protection
against bronchoconstrictor-induced increases in respiratory resistance provided by
nebulizing retigabine (Figure 22). In some instances nebulizing retigabine
appeared to increase the sensitivity to bronchoconstrictor challenge, however this
may be a result of the repetitive administration of the bronchoconstrictor and not
necessarily due to the retigabine treatment. Another consideration is that both
methacholine and histamine result in an increase in mucus secretion (Boat and
Kleinerman 1975, Webber and Widdicombe 1987). This mucus secretion may
result in airflow obstruction that is not always detectable using our current
methods. In some instances the sinusoidal waveform produced during the
“snapshot” maneuver may indicate the presence of an obstruction, however little
can be done to remove that obstruction once it occurs. A different approach
minimalizing bronchoconstrictor treatment may be considered to avoid this
potential side effect, but we intended to use each animal as its own control for
consecutive
experiments.

dose-response

challenges

for

these

particular

optimization
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Although we did not observe consistent retigabine-induced protection
during

bronchoconstrictor

challenges,

nebulizing

retigabine

during

the

“pretreatment” period did lower respiratory resistance levels below the initial
baseline levels recorded prior to the first bronchoconstrictor challenge (Figure 23).
This suggests that retigabine is being delivered to the airways and is having some
bronchodilatory effect, however the therapeutic relevance of this effect remains to
be determined.
Overall, our results indicate that activation of Kv7 channels represents a
novel approach to bronchodilation in vitro, however developing an in vivo model to
test the effectiveness of retigabine at relieving bronchoconstriction, particularly in
asthmatic airways, is essential for the continuation of this project. One thing that
may be important to note is that the initial optimization flexiVent studies utilized
naïve guinea pigs; no OVA-sensitized guinea pigs were tested. It would be
interesting to asses if retigabine offers protection to OVA-sensitized guinea pigs,
either from their hypersensitivity to bronchoconstrictor agonists or from OVAinduced bronchoconstriction. It is possible that retigabine may be effective at
attenuating exaggerated responses to bronchoconstrictor agonists that are
typically associated with this animal model (Kakad 2012). Our in vivo pilot study
demonstrated the ability of retigabine to attenuate OVA-induced allergic responses
typically observed in the unanesthetized OVA-sensitized guinea pigs. Perhaps
retigabine would be effective at relieving the bronchoconstriction associated with
an asthmatic response that is associated with a specific allergen, as our pilot study

105
suggests. The anesthetic used may also be interfering with our flexiVent studies.
However, our pilot studies completed in conscious animals are more
representative of the desired delivery method for retigabine (conscious, inhalation)
and suggest the effectiveness of this drug at alleviating the symptoms associated
with allergic asthma.
The difficulties experienced with the guinea pig model imply that it may be
beneficial to adopt a new model of allergic asthma to determine if Kv7 channel
activators are efficacious bronchodilators. There are a number of different rat
models that can be used to study asthma (Kucharewicz, Bodzenta-Lukaszyk et al.
2008). Although Sprague Dawley rats, the species of rat used in our laboratory for
PCLS experiments, do not develop an allergic reaction to OVA (Olivenstein, Renzi
et al. 1993, Sirois and Bissonnette 2001), they can be used as a control group for
Brown Norway OVA-sensitized rats (Careau and Bissonnette 2004). This would
allow for a comparison of the bronchodilator effects of Kv7 channel activators to
be compared more thoroughly in sensitized and non-sensitized rat airways. The
difficulty we recently experienced using guinea pigs and guinea pig tissue, even in
non-sensitized animals, only served to highlight the ease and reproducibility we
observed when using rat tissue for previous studies. It would be interesting to see
if this ease of use extends to sensitized rats and their tissue. There are also a
variety of well-established mouse models (Nials and Uddin 2008, Shin, Takeda et
al. 2009) that can be used to examine the therapeutic potential of Kv7 channel

106
activators that should be considered for addressing the potential of moving
retigabine to clinical trials.
In summary, the bronchoconstrictor agonist histamine induces PKCdependent hKv7.5 channel phosphorylation and subsequent inhibition of hKv7.5
currents in cultured human trachealis smooth muscle cells. PKCα appears to be
necessary for current suppression by the bronchoconstrictor as well as partially
necessary for sustained elevation of [Ca2+]cyt following treatment of HTSMCs with
histamine. However, our biochemical analysis of phosphorylation of hKv7.5 by
PKC indicates that additional PKC isoforms may also be phosphorylating the
channel. Similarly, serine residue 441 appears to be necessary for histamineinduced hKv7.5 current inhibition but our phosphorylation studies indicate that
additional amino acid residues are also phosphorylated following histamine
treatment, though these residues may not have an impact on the channel’s
function. These findings, along with the other work presented in this dissertation,
help to shed light on the ionic mechanisms involved in the regulation of airway
smooth muscle contractility.
The bronchodilatory capacity of Kv7 channel activators was also explored.
The clinically available Kv7 channel activator retigabine relaxed rat, guinea pig,
and human airways in vitro, however an in vivo allergic asthma animal model that
can be used to examine the therapeutic potential of retigabine to relax airway
smooth muscle has yet to be developed. The work presented in this dissertation
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has created a solid foundation for future studies that explore the potential of Kv7
channel activators as novel asthma therapeutics.
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